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SUMMARY  28 
Fructose-1,6-bisphosphate (FBP) aldolase links sensing of declining glucose 29 
availability to AMPK activation via the lysosomal pathway. However, how aldolase 30 
transmits lack of occupancy by FBP to AMPK activation remains unclear. Here, 31 
we show that FBP-unoccupied aldolase interacts with and inhibits endoplasmic 32 
reticulum(ER)-localized transient receptor potential channel subfamily V, 33 
inhibiting calcium release in low glucose. The decrease of calcium at contact sites 34 
between ER and lysosome renders the inhibited TRPV accessible to bind the 35 
lysosomal v-ATPase that then recruits AXIN:LKB1 to activate AMPK, 36 
independently of AMP. Genetic depletion of TRPVs blocks glucose starvation-37 
induced AMPK activation in cells and liver of mice, and in nematodes, indicative 38 
of physical requirement of TRPVs. Pharmacological inhibition of TRPVs activates 39 
AMPK and elevates NAD+ levels in aged muscles, rejuvenating the animals’ 40 
running capacity. Our study elucidates that TRPVs relay the FBP-free status of 41 
aldolase to the reconfiguration of v-ATPase, leading to AMPK activation in low 42 
glucose. 43 
Keywords: glucose sensing, AMPK, TRPV, aldolase, v-ATPase 44 
INTRODUCTION 45 
AMP-activated protein kinase (AMPK) is a pivotal sensor for monitoring cellular 46 
energy state and nutrient supply (Carling et al., 2012; Herzig and Shaw, 2017; Lin and 47 
Hardie, 2017; Steinberg and Kemp, 2009). It occurs universally as heterotrimeric 48 
complexes containing catalytic  subunits and regulatory  and  subunits, with the  49 
subunit providing the binding sites for the regulatory adenine nucleotides, AMP, ADP 50 
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and ATP. When cells encounter metabolic stress, an increase of AMP:ATP and 51 
ADP:ATP ratios occurs. Binding of AMP to AMPK causes allosteric activation. 52 
Moreover, binding of AMP or ADP, also enhances phosphorylation of Thr172 on the 53 
-subunit by the upstream kinase liver kinase B1 (LKB1), and inhibits Thr172 54 
dephosphorylation by protein phosphatases; all three effects are opposed by binding of 55 
ATP (Ross et al., 2016). Thr172 can also be phosphorylated by the alternative upstream 56 
kinase Ca2+/calmodulin-dependent protein kinase kinase-2 (CaMKK2/CaMKK) in 57 
response to increases in cytosolic Ca2+ concentration (Hawley et al., 2005; Hurley et 58 
al., 2005; Woods et al., 2005). Once activated, AMPK phosphorylates a wide range of 59 
downstream targets to maintain energy homeostasis, switching on catabolic pathways 60 
that generate ATP while switching off ATP-consuming processes (Herzig and Shaw, 61 
2017). We have recently shown that glucose deprivation activates AMPK in an 62 
AMP/ADP-independent manner through a mechanism involving the scaffold protein 63 
axis inhibitor protein (AXIN) (Zhang et al., 2017). AXIN binds LKB1 constitutively, 64 
but glucose deprivation promotes formation of a ternary complex that includes the 65 
downstream kinase AMPK (Zhang et al., 2013). This occurs on the surface of the 66 
lysosome and requires both the vacuolar H+-ATPase (v-ATPase, which acidifies the 67 
lumen of lysosomes) and the pentameric Ragulator complex containing LAMTOR1-68 
LAMTOR5 (Zhang et al., 2013). The v-ATPase-Ragulator complex is also required in 69 
a reciprocal manner for activation of mTORC1 when nutrient levels are high, thus 70 
exerting a reversible switch between catabolism and anabolism (Zhang et al., 2014). 71 
Upon glucose deprivation, a proportion of aldolase becomes unoccupied by fructose-72 
1,6-bisphosphate (FBP) and acts as a sensor of glucose availability to promote docking 73 
of AXIN:LKB1 to the v-ATPase:Ragulator complex, which in turn leads to the 74 
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formation of a “super-complex” comprised of the v-ATPase, Ragulator, AXIN, LKB1 75 
and AMPK on the lysosomal surface, referred to below as the AXIN-based complex, 76 
and thereby allows LKB1 to phosphorylate and activate AMPK (Zhang et al., 2017; 77 
Zhang et al., 2014; Zhang et al., 2013). Importantly, inhibition of v-ATPase upon 78 
glucose starvation is a prerequisite step in triggering the lysosomal pathway because 79 
concanamycin A (ConA), a v-ATPase inhibitor (Drose and Altendorf, 1997), is able to 80 
directly promote the formation of the AXIN-based complex even under normal glucose 81 
conditions (Zhang et al., 2014). However, it remained unclear how the FBP-unoccupied 82 
aldolase leads to inhibition of v-ATPase that allows for the formation of the AXIN-83 
based complex.  84 
RESULTS 85 
TRPV1-4 Interact with FBP-unoccupied Aldolase and Are Required for 86 
Lysosomal AMPK Activation in Low Glucose 87 
To search for factors that might transmit sensing of the absence of FBP by aldolase to 88 
the conformational changes of v-ATPase, we performed mass spectrometry of protein 89 
complexes co-immunoprecipitated with ALDOA from light organelle fractions 90 
containing lysosomes. Some 114 proteins with cutoff scores >3.69 were obtained (Table 91 
S1), which could be divided into four major categories, as summarized in Figure S1A. 92 
Among them, there were multiple known interactors of aldolase, including the v-93 
ATPase subunits V1A, V1B2, and V1E1 (Bond and Forgac, 2008; Lu et al., 2007; Lu 94 
et al., 2001; Lu et al., 2004), the glycolytic enzymes GAPDH and PFK1 (Ouporov et 95 
al., 2001; Ovádi and Sreret, 1999), and components of actin and tubulin filaments (Carr 96 
and Knull, 1993; Wang et al., 1996). We were intrigued by one candidate, TRPV4, 97 
which belongs to the V subfamily of transient receptor potential (TRP) channels, which 98 
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play a variety of roles in different tissues in response to chemical and physical stimuli 99 
(Clapham, 2003; Nilius and Flockerzi). As with other members of this family, TRPV4 100 
has been shown to be localized both to the plasma membrane and endomembrane 101 
systems, including the endoplasmic reticulum (ER) (Wen et al., 2017). We also 102 
confirmed that a portion of TRPV4 is localized on ER by performing subcellular 103 
fractionation (Figures S1B and S1C). We next carried out co-immunoprecipitation 104 
assays to validate the interaction between aldolase and TRPV4 in the presence or 105 
absence of FBP. Co-immunoprecipitation was detected between TRPV4 and all the 106 
three isozymes of aldolase (Figure S1D). Importantly, these interactions were virtually 107 
abolished in the presence of 10 µM (and above) FBP (Figure 1A), which is within the 108 
range of FBP concentrations in cells cultured with normal glucose (Zhang et al., 2017). 109 
These results demonstrated that aldolase interacts with TRPV4 only in the absence of 110 
FBP.  111 
We next tested whether TRPV4 is involved in regulating the lysosomal AMPK 112 
activation pathway. However, unlike LAMTOR1 deficiency, which leads to a defect of 113 
AXIN/LKB1 docking onto the lysosome for AMPK activation (Zhang et al., 2014), 114 
knockout of TRPV4 in MEFs only partially blocked the activation of AMPK in low 115 
glucose, as determined by the phosphorylation of Thr172 on AMPKand of the 116 
primary site on the AMPK downstream target, ACC (Figure 1B), a key marker for 117 
determining AMPK activity in intact cells (Gowans et al., 2013). The mammalian 118 
TRPV subfamily contains five other structurally conserved members (Nilius and 119 
Flockerzi), suggesting that other family members might be involved in AMPK 120 
activation. MEFs expressed mRNAs encoding TRPV1-4, with that for TRPV4 being the 121 
most abundant, while TRPV5 and TRPV6 mRNAs were not detected (Figure S1E); 122 
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however only TRPV1 and TRPV4, and not TRPV2 or TRPV3, were detectable by 123 
Western blotting. Validation of the TRPV1 and TRPV4 antibodies, using lysates from 124 
TRPV1-/- or TRPV4-/- MEFs, are shown in Figures S1B and S2B. We next tested 125 
interactions between TRPV1 or TRPV4 and aldolase, using either ectopically expressed 126 
or endogenous proteins. TRPV1-3, like TRPV4, all showed interactions with aldolase 127 
in the absence of FBP (Figures 1C, S1F, S1H to S1J; antibody against endogenous 128 
aldolase was validated in Figure S1G), and similar to that of TRPV4, single knockout 129 
of TRPV1, TRPV2 or TRPV3 only mildly impaired the activation of AMPK upon 130 
glucose starvation (Figure 1B). We therefore carried out a quadruple knockout of 131 
TRPV1-4 in MEFs (TRPV-QKO, Figures S2A and S2B), and found that this markedly 132 
impaired the effects of glucose starvation on the inhibition of v-ATPase, lysosomal 133 
translocation of AXIN, formation of the AXIN-based complex, and AMPK activation 134 
(Figures 1B and 1D to 1F, S2C and S2D). Importantly, the requirement of TRPVs 135 
covered the entire physiological range of glucose (5 mM and below) for AMPK 136 
activation in vivo (Figure 1G) (Zhang et al., 2017). Re-introduction of a single TRPV 137 
channel by stable expression in TRPV-QKO MEFs restored AMPK activation upon 138 
glucose starvation (Figure S2E, and mRNA levels of four re-introduced TRPVs were 139 
validated in Figure S2F). These results confirmed that TRPV1-4 are functionally 140 
redundant in glucose sensing in MEFs. They appear to be specifically involved in 141 
AMPK activation induced by glucose starvation, because treating TRPV-QKO MEFs 142 
with oligomycin or dinitrophenol (inhibiting oxidative metabolism), sorbitol 143 
(generating osmotic stress), hydrogen peroxide(generating oxidative stress), or 144 
A769662 (direct binding to AMPK) (Langendorf and Kemp, 2015; Xiao et al., 2013), 145 
all still led to robust AMPK activation (Figure 1H). The importance of TRPV1-4 in 146 
AMPK activation was further supported by genetic evidence that starvation-induced 147 
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AMPK activation was severely impaired in mouse liver or primary hepatocytes from 148 
TRPV1-/- mice with knockdown of TRPV2-4 (Figures 1I, 1J, S2H and S2I, note that in 149 
mouse liver, TRPV5 and TRPV6 were not expressed, as validated in Figure S2G) with 150 
the plasma glucose levels unchanged compared with wildtype littermates (Figure S2J). 151 
Importantly, in C. elegans mutants lacking both osm-9 and ocr-2, the mammalian TRPV 152 
orthologs (Colbert et al., 1997; Tobin et al., 2002; Zhang et al., 2004), glucose 153 
restriction failed to activate AMPK (Figures 1K). Thus, TRPV members represent 154 
newly identified factors that play essential roles in glucose-sensing and AMPK 155 
activation via the lysosomal pathway in an evolutionarily conserved manner. 156 
Glucose Starvation Blocks the Ca2+ Channel Activity of TRPVs 157 
We next tested whether the channel activity of TRPVs is affected by glucose starvation. 158 
We engineered a Ca2+ indicator by fusing GCaMP6s (Chen et al., 2013) to the 159 
cytoplasmic tail of TRPV4. The channel activity was directly monitored by the green 160 
fluorescence elicited by the indicator upon binding Ca2+ (the proper subcellular 161 
localization of the indicator was validated in Figure S3A; and the intact function of the 162 
fused indicator in sensing calcium was validated in Figures S3B and S3C). Indeed, the 163 
TRPV4-GCaMP6s fluorescent signal was strongly inhibited within 10 min of glucose 164 
starvation (Figure 2A) without any alteration of the cytosolic pH (Figure S3D), by 165 
which time AMPK is fully activated (Zhang et al., 2017).  166 
Many agonists for TRPV channels have been identified, including capsaicin 167 
(Caterina et al., 1997) for TRPV1, carvacrol (Xu et al., 2006) for TRPV3, and GSK101 168 
(Thorneloe et al., 2008) and RN1747 (Vincent et al., 2009) for TRPV4 (Figure 2B). 169 
Consistently, capsaicin, carvacrol, RN1747 or GSK101 led to robust increases in 170 
fluorescence of the Ca2+-sensitive dye, Fura-2, in glucose-starved MEFs (Figure S3E). 171 
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The three agonists also increased the acidity in lysosomes in glucose-starved MEFs, as 172 
evidenced by the increased signal of the LysoSensor Green DND-189 dye (Figures 2C 173 
and S3F) whose signal increases when lysosomal pH is lowered (Cousin and Nicholls, 174 
1997), indicating that they restored the activity of the v-ATPase in glucose-starved cells. 175 
Consistently, these agonists blocked the lysosomal translocation of AXIN and AMPK 176 
activation upon glucose starvation (Figures 2D, S3G and S3H). Similar effects were 177 
observed using 2-APB (TRPV1-3 agonist (Hu et al., 2004)) in TRPV1/3/4 triple KO 178 
(TKO) MEFs in which only TRPV2 was expressed (Figures S3I and S3J). No change 179 
in AMP:ATP and ADP:ATP ratios was observed in glucose-starved MEFs following 180 
treatment with these agonists, unlike phenformin (Figure S3K). These results further 181 
confirmed that TRPV1-4 although expressed at different levels, can function 182 
redundantly upstream of the v-ATPase in MEFs (Figures 1B, S1E and S2E). These 183 
results demonstrate that it is the v-ATPase activity that is regulated by TRPVs, and 184 
which in turn regulates AMPK activation. 185 
We also used TRPV antagonists to test whether blocking the channels would mimic 186 
glucose starvation. AMG-9810 is an antagonist originally designed to inhibit TRPV1 187 
(Gavva et al., 2005), but several studies have found that it also inhibits other TRPV 188 
family members such as TRPV4 (Ye et al., 2012). Indeed, AMG-9810 dampened the 189 
Fura-2 signal in TRPV1-/- MEFs (Figure S4A). AMG-9810 also dampened the Fura-2 190 
signal in TRPV-QKO MEFs rescued by expression of TRPV2, TRPV3 or TRPV4 191 
(Figure S4B). We found that AMG-9810 directly triggered lysosomal complex 192 
formation and AMPK activation in MEFs cultured in normal glucose, but not in TRPV-193 
QKO MEFs (Figures 2F, 2G, S4C and S4D). As an additional control, no further 194 
decrease in TRPV4-GCaMP6s signal was detected in MEFs pre-treated with AMG-195 
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9810 (Figure S4E). Importantly, knockout of LKB1, but not CaMKK2, abolished 196 
AMPK activation by AMG-9810 (Figures S4F and S4G). We also confirmed that there 197 
is no change in AMP:ATP and ADP:ATP ratios in MEFs treated with AMG-9810 198 
(Figure S4H). Thus, TRPVs, at least 1-4, in their closed state triggers the lysosomal 199 
AMPK activation pathway upstream of the v-ATPase:Ragulator complex.  200 
TRPVs Maintain a Compartmentalized Ca2+ Concentration at ER-lysosome 201 
Contact Sites in Normal Glucose  202 
As TRPVs are cation channels, we addressed whether Ca2+ released by TRPVs exert 203 
effects on the lysosomal AMPK pathway. Since TRPV1-4 redundantly regulate AMPK, 204 
we chose TRPV4 as a representative example. Re-introduction into TRPV-QKO MEFs 205 
of D672A or D682A mutants of TRPV4, which are defective (also confirmed as in 206 
Figures S5A and S5B) in channel function (Owsianik et al., 2006; Voets et al., 2002), 207 
led to constitutive AMPK activation (Figures 3A). Addition of BAPTA-AM, a cell-208 
permeable calcium chelator (Tsien, 1980), was also sufficient to trigger AMPK 209 
activation through the lysosomal pathway both in vivo and in vitro (Figures 3B to 3E, 210 
and S5C). BAPTA-AM also blocked the effects of channel agonists on the lysosomal 211 
translocation of AXIN (Figure 3F). The calcium chelator EGTA-AM, which binds Ca2+ 212 
more slowly than BAPTA-AM (Stern, 1992; Tsien, 1980), did not trigger the lysosomal 213 
pathway (Figures 3H), suggesting that Ca2+ release from TRPVs that suppresses AMPK 214 
activation in normal glucose was local and transient. This agrees with results that 215 
glucose starvation did not cause changes in bulk Ca2+ concentrations, as recorded by 216 
cytosol-localized Fluo-3 (Figure 4A).  217 
We then used imaging techniques to determine if TRPV4 has co-localization with 218 
the lysosomal marker LAMP2. We indeed observed juxtaposition of TRPV4 with 219 
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LAMP2, as revealed by immunofluorescent staining using confocal microscopy (Figure 220 
S5D). Imaging by Structured Illumination Microscopy (SIM) also showed that 17.17 ± 221 
5.7% of TRPV4 puncta (2,337 of 14,160, counted in 11 cells) were juxtaposed with 222 
LAMP2 (Figure S5F, validated in Figure S5E). We also performed Stochastic Optical 223 
Reconstruction Microscopy (STORM) to study the organization of TRPV4-lysosomal 224 
foci in vivo at the nanometer scale, and the results clearly showed that a portion of 225 
TRPV4 is located in apposition to LAMP2 (Figure 4B). To confirm the Ca2+ levels in 226 
the immediate vicinity of lysosomes, GCaMP6s was fused to the cytosol-facing C-227 
terminus of the lysosomal marker LAMP2 (LAMP2-GCaMP6s, Figure 4C, validated 228 
in Figure S5G). We found that glucose starvation strongly blunted the fluorescent signal, 229 
in line with the majority of LAMP2 puncta (1,621 of 1,935 or 87.44 ± 5.6%, counted 230 
in 11 cells from SIM images) being juxtaposed with TRPV4. These findings are also 231 
consistent with the reported observation that over 95% of lysosomes are in apposition 232 
to ER via ER-lysosome contact sites (Rowland et al., 2014). It is therefore reasonable 233 
to suggest that the Ca2+ ions released by TRPV4 comes from the ER Ca2+ pool. Indeed, 234 
no changes in TRPV4-GCaMP6s signals were detected in MEFs treated with 235 
thapsigargin, a drug that depletes ER calcium stores (Figures 4D, left panel, and S5H). 236 
In comparison, depletion of extracellular Ca2+ had no effect on TRPV4-GCaMP6s 237 
intensity during glucose starvation or under TRPV4-specific agonist GSK101 238 
stimulation (Figures 4D, right panel, and S5I). As an additional control, GSK101 could 239 
still increase signals of Fura-2 in MEFs with extracellular Ca2+ depleted, while 240 
knockout of TRPV4 rendered GSK101 ineffective (Figure S5J). Moreover, GSK101 241 
failed to inhibit glucose-starvation-induced AMPK activation after the ER pool of Ca2+ 242 
had been depleted by thapsigargin (Figure 4E).  243 
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It is well established that increases in bulk cytosolic Ca2+ activate AMPK via 244 
CaMKK2, unlike the localized pool of Ca2+ released from TRPV channels, which 245 
inhibits AMPK activation in normal glucose. We previously showed that the Ca2+ 246 
ionophore A23187 readily activates AMPK in AXIN-/- and LAMTOR1-/- MEFs via 247 
CaMKK2 (Zhang et al., 2014), distinct from the lysosomal pathway that requires AXIN 248 
and LAMTOR1 and is independent of CaMKK2 (Zhang et al., 2017). Similarly, TRPV 249 
agonists failed to evoke CaMKK2 signaling, as monitored by phosphorylation of 250 
CaMKI, another substrate of CaMKK2 (Figure 4G). In addition, in glucose starved 251 
CaMKK2-/- MEFs was fully suppressed by the TRPV4 agonist GSK101 (Figure 4F), 252 
and AMG-9810 still activated AMPK in CaMKK2-/- MEFs (Figure S4G). Furthermore, 253 
while EGTA-AM could not ablate the suppression of glucose starvation-induced 254 
AMPK activation by the agonist GSK101, it suppressed CaMKK2-dependent AMPK 255 
activation by ionomycin (Figures S5K to S5N).  256 
Finally, we attempted to reconstitute v-ATPase regulation by re-introducing 257 
TRPV4 and Ca2+ to purified lysosomes. Addition of TRPV4 alone inhibited the v-258 
ATPase activity, co-addition of Ca2+ relieved the inhibitory effect (Figures 4H and 4I), 259 
recapitulating that local Ca2+ is required to maintain v-ATPase activity.  260 
Aldolase Inhibits Ca2+ Channel Activity of TRPV4 in Low Glucose/FBP 261 
We next determined how low glucose inhibits TRPV channels via aldolase. TRPV4 was 262 
tested as a representative. Knockdown of aldolases blocked the effects of glucose 263 
starvation in dampening the fluorescent signal obtained with TRPV4-GCaMP6s and 264 
LAMP2-GCaMP6s (Figure 5A compare with Figures 2A and S6A), indicating that 265 
aldolase is required to block the TRPV4. Importantly, ectopic expression of ALDOA-266 
D34S, which binds FBP constitutively, failed to dampen the signal of TRPV4-267 
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GCaMP6s and LAMP2-GCaMP6s (Figures 5B, 5C and S6B), indicating that FBP-268 
occupied aldolase is unable to trigger closure of TRPV4. We conclude that TRPV4 is 269 
inhibited by aldolase when it is unoccupied by FBP, i.e., under glucose starvation 270 
conditions. Interestingly, signals of TRPV4-GCaMP6s, not only those localized on ER-271 
lysosome contact sites, but also on other parts of the cell, were controlled by aldolase 272 
and FBP (see Figure 5C, in which a universally decreased of TRPV4-GCaMP6s signals 273 
could be detected). This finding indicates that different pools of TRPV4 can be similarly 274 
inhibited by FBP-unoccupied aldolase as aldolase is ubiquitously localized inside cells 275 
(apart from those interact with v-ATPase). However, it is important to note that only the 276 
portion of TRPV4 localized in the vicinity of lysosome has the chance to modulate v-277 
ATPase on the lysosome. As mentioned earlier, aldolase unoccupied by FBP shows 278 
strong interaction with TRPVs (e.g., Figures 1A, 1C and S1F). We therefore tested 279 
whether inhibition of TRPV4 is caused by binding of aldolase. We found that the 280 
activity of a K535A mutant of TRPV4, which was unable to bind aldolase (identified 281 
by deletion mapping followed by alanine mutagenesis screening, as shown in Figures 282 
5D and S6C to S6F), was still capable of being regulated by its agonist and antagonist, 283 
as determined by a TRPV4-GCaMP6s-K535A indicator (Figures 5E and S6G), while 284 
AMPK activation was reduced in QKO MEFs in which this mutant was re-expressed 285 
(Figure 5F). Similarly, truncated ALDOA (residues 1-345, i.e. lacking the C-terminal 286 
19 amino acids), which was defective in binding to TRPV1 to TRPV4, failed to rescue 287 
the AMPK activation when re-introduced into ALDO-TKD MEFs (Figures 5G, S6H 288 
and S6I). These results reinforced the importance of the aldolase-TRPV interaction in 289 
blocking channel activity and causing AMPK activation.   290 
Inactivated TRPV4 Protein after Ca2+ Depletion Physically Reconfigures the 291 
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Association of Aldolase with v-ATPase 292 
We next analyzed how the interplay between aldolase and TRPV affects the v-ATPase 293 
and AMPK activation. It is well established that aldolase directly interacts with various 294 
subunits of the v-ATPase, and is required for its activity (Lu et al., 2007; Lu et al., 2004). 295 
Indeed, knockdown of aldolase directly activates AMPK in both WT and TRPV-QKO 296 
MEFs (Figure 6A). It thus appears that aldolase unoccupied by FBP is somehow 297 
dissociated from the v-ATPase, driving the v-ATPase to undergo changes that lead to 298 
AMPK activation instead. However, when we re-introduced the K230A mutant of 299 
aldolase, which cannot form the initial Schiff base with the substrate FBP and thus 300 
causes constitutive AMPK activation (Morris and Tolan, 1993; Zhang et al., 2017), 301 
AMPK was not activated in the TRPV-QKO MEFs (Figure 6B). Therefore, the absence 302 
of FBP from aldolase is not sufficient to cause AMPK activation, but it also requires 303 
the physical presence of inactivated TRPVs, such as TRPV4, for re-configuring the 304 
aldolase-v-ATPase interaction, eliciting the ultimate conformational change of v-305 
ATPase for AMPK activation. Indeed, we found that TRPV4 interacts with v-ATPase 306 
in glucose-starved cells (Figure 6C). Addition of both FBP and CaCl2 (mimicking the 307 
effect of normal glucose) to lysates prepared from glucose-starved cells strengthened 308 
the association between ALDOA and v-ATPase, along with attenuation of the 309 
TRPV4:v-ATPase interaction (Figures 6C and 6D). These results imply that the 310 
association of aldolase or TRPV4 with v-ATPase may be mutually exclusive. 311 
Consistent with this, increased expression of TRPV4 disrupted the interaction between 312 
ALDOA and v-ATPase, accompanied by an increase of association between TRPV4 313 
and the v-ATPase, but this was not observed in normal glucose (Figure 6E). Importantly, 314 
knockout of TRPV1-4 led to a constant interaction between ALDOA and v-ATPase 315 
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even in the absence of FBP and CaCl2 (Figure 6F). Moreover, the truncation mutant 316 
TRPV4-Δ1-144, which is defective in binding to the v-ATPase, failed to mediate 317 
AMPK activation upon glucose starvation, and did not inhibit the activity of v-ATPase 318 
based on in vitro reconstitution experiments (Figures 6G, 6H, and S7A). These 319 
observations, together with those showing the requirement of TRPV activity in 320 
lysosomal AMPK activation (Figure 2), point to the same conclusion, i.e. that TRPV1-321 
4 are required both physically and functionally for lysosomal AMPK activation in 322 
response to low glucose.  323 
We next dissected the roles of FBP and Ca2+ in the interaction between aldolase 324 
and v-ATPase by adding them singly to lysates from starved cells. FBP decreased the 325 
interaction between ALDOA and TRPV4 (Figures 6C and 6D). By contrast, incubation 326 
with CaCl2 prevented interaction between TRPV4 and v-ATPase, restoring the 327 
interaction between ALDOA and v-ATPase (Figures 6C and 6D), consistent with Ca2+ 328 
being able to activate v-ATPase in vitro, as shown in Figures 4H and 4I. Importantly, 329 
ALDOA interacts with TRPV4 as long as FBP is low, regardless of Ca2+ concentrations 330 
(Figures 6C and 6D). This indicates that the binding of FBP-unoccupied aldolase to 331 
TRPV4, prior to the change in Ca2+, is the priming step that triggers the glucose-sensing 332 
cascade. Subsequently, the reduced level of Ca2+ enhances the interaction of TRPV4 333 
with v-ATPase, re-configuring the aldolase:v-ATPase complex into a ternary 334 
aldolase:TRPV4:v-ATPase “sandwich”. The existence of an aldolase:TRPV4:v-335 
ATPase complex was further confirmed by a two-step co-immunoprecipitation assay, 336 
showing that all three components were detected in the final immunoprecipitates 337 
generated from glucose-starved cells (Figure 6I).  338 
The v-ATPase is an electrogenic pump, and its activity in proton transport is 339 
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maintained both by ATP hydrolysis (directly providing energy for proton transport 340 
against an electrochemical gradient) and flux of counter-ions (dissipating the electrical 341 
potential across the lysosomal membrane generated by proton accumulation) (Nishi and 342 
Forgac, 2002). We thus determined whether the lysosomal counter-ion flux was 343 
suppressed under glucose starvation conditions, by directly measuring the lysosomal 344 
membrane potential at different time points of glucose starvation through an in vivo 345 
FRET-based method (Koivusalo et al., 2011). The result showed that the lysosomal 346 
membrane potential hardly changed under glucose starvation (Figure 6J, validated in 347 
S7B). This suggests that the inhibition of v-ATPase during glucose deprivation is not 348 
caused by restraint on proton accumulation, or a defect in counter-ion conductance. 349 
Combining the observation that the V1 and v0 domains of v-ATPase were still present 350 
in purified lysosomes from cells starved of glucose for 4 hr (Figure S7C), we conclude 351 
that aldolase and the v-ATPase are not dissociated in low glucose, as has been reported 352 
in the yeast system (Lu et al., 2004).  353 
Inhibition of TRPV1-4 Increases Physical Fitness in Aged Mice 354 
Finally, we tried to explore potential pharmacological effects of TRPVs as regulators 355 
of AMPK. The age-related metabolic decline and reduced fitness result in decreased 356 
exercise capacity, which has been recognized as a strong predictor of morbidity and 357 
mortality in humans (Paffenbarger et al., 1993; Sandvik et al., 1993). Activation of 358 
AMPK is well known as a way to improve physical fitness by promoting fatigue 359 
resistance and the malleability of muscle (Bujak et al., 2015; Narkar et al., 2008; 360 
Steinberg and Jorgensen, 2007), and in fact has been proposed as a promising way to 361 
retard aging-associated syndromes (Burkewitz et al., 2014). Unfortunately, AMPK in 362 
aged muscle is difficult to be activated by exercise or even pharmacological drugs such 363 
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as AICAR (Ljubicic and Hood, 2009; Park et al., 2017; Reznick et al., 2007). We thus 364 
tested the effects of AMG-9810, an inhibitor to TRPV1-4 that activates AMPK, in 1.5-365 
year-old mice. It was found that administration of the drug activated AMPK in the mice, 366 
without altering the adenylate ratios (Figures 7A and 7B). Importantly, AMG-9810 367 
caused much greater AMPK activation in aged muscles compared with A-769662 and 368 
phenformin, two classical activators of AMPK (Figure 7A). Strikingly, AMG-9810, 369 
after two months of administration, doubled the running capacity of the aged mice 370 
(Figure 7C). As NAD+ has been shown to be increased by AMPK (Canto et al., 2009), 371 
and is regarded as a symbol of physical fitness including running capacity (Zhang et al., 372 
2016), we measured the levels of NAD+, and found that AMG-9810 indeed elevated 373 
levels of NAD+ (Figure S7D). Importantly, this effect was impaired when AMPKβ2, a 374 
muscle-specific isoform of AMPK, was knocked down (Figure 7D). Taken together, 375 
these results indicate that inhibition of TRPV1-4 provide a way to overcome the 376 
difficulty to activate AMPK in aged animals.  377 
DISCUSSION 378 
In the current study, we have unveiled a missing link in glucose sensing, specifically 379 
between the lack of FBP-binding to aldolase and the formation of the lysosomal 380 
AMPK-activation complex. When glucose supply is abundant, FBP-occupied aldolase 381 
binds to the v-ATPase and acts as an integral component to maintain its activity. In low 382 
glucose, FBP-unoccupied aldolase interacts with juxtaposed TRPV1-4 channels to 383 
suppress their channel activity. As a result, the local Ca2+ concentration decreases at the 384 
ER-lysosome contact site, which in turn renders TRPV1-4 accessible to the v-ATPase, 385 
generating a ternary complex between aldolase, TRPV and the v-ATPase. The v-386 
ATPase is thus inhibited, promoting the translocation of the AXIN:LKB1 complex to 387 
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the lysosome and leading to AMPK activation (Figure 7E). A conceivable advantage of 388 
inserting another step between aldolase and the v-ATPase is that TRPV channels, along 389 
with fluctuations in their released calcium ions, act as buffers or dampers that prevent 390 
the activity of v-ATPase from oscillating too rapidly. Even when bound to actin 391 
filaments that inhibit the enzyme (Hu et al., 2016), aldolase exhibits a high rate in 392 
converting FBP to phosphotrioses, undergoes rapid cycles between FBP-bound and 393 
unbound states. This might lead to severe oscillations in v-ATPase activity if the latter 394 
was directly controlled by the availability of FBP to aldolase. The localized release of 395 
Ca2+, which would be retrieved by various nearby Ca2+ transporters and pumps or be 396 
lost by diffusion into the cytosolic space nearby, is tightly clamped and thus remains at 397 
a relatively constant level, preventing TRPV1-4 from interacting with v-ATPase 398 
(Mulier et al., 2017; Nita et al., 2016). However, as glucose availability drops, a greater 399 
percentage of aldolase would become unoccupied by FBP and more TRPV1-4 channels 400 
would be inhibited, leading to a decrease of the local Ca2+ concentration. There might 401 
be a threshold below which the local Ca2+ concentration must drop to allow the v-402 
ATPase to interact with TRPV1-4, thus triggering interaction of AXIN:LKB1 with the 403 
lysosome and AMPK activation. Therefore, the involvement of TRPV/Ca2+ may buffer 404 
oscillations in FBP, like an electric capacitor that filters out fluctuations when attached 405 
to an electronic circuit, and provides a more graded regulation of v-ATPase (Figure 406 
S7E). With the involvement of TRPV1-4 channels, our work has successfully 407 
reconstituted the effects of glucose availability on the v-ATPase, thus resolving a long-408 
standing question in this field (Kane, 2012). Of note, a recent study showed that 409 
combined starvation of glucose and serum might even increases acidity of newly 410 
generated lysosomes before increases of autophagic fluxes (McGuire and Forgac, 2018). 411 
19 
  
Our study may also suggest a new type of TRPV1-4 activation. Traditionally, 412 
TRPV1-4 are known to be stimulated by physical and chemical signals. Here, we found 413 
that the TRPV1-4 are constitutively active, by default, so long as glucose is present and 414 
no aldolase is in contact with the channels. It is also noteworthy that different 415 
concentrations of TRPV agonists might yield differing results in the context of AMPK 416 
activation. For example, it has been reported that capsaicin results in AMPK activation 417 
in a Ca2+- and CaMKK2-dependent manner (Kim et al., 2013). However, the 418 
concentrations of capsaicin used in those studies (>10 µM) were much higher than that 419 
used here (100 nM), and may have caused a bulk, global increase in Ca2+ concentration 420 
that might also be blocked by EGTA-AM (Ching et al., 2012; Ying et al., 2013). Thus, 421 
excessively high concentrations of capsaicin may cause activation of AMPK via a 422 
mechanism different from that studied here. 423 
Another interesting issue is the reciprocal regulation of AMPK and mTORC1, as 424 
glucose-sensing and amino acid-sensing on the lysosome share use of the same v-425 
ATPase:Ragulator complex (Zhang et al., 2014). One unanswered question is why 426 
amino acid starvation does not activate AMPK, while glucose starvation activates 427 
AMPK and concomitantly inhibits mTORC1. We show here that amino acid starvation 428 
does not affect the activity of TRPV4 (Figure S7F). Furthermore, TRPV agonists 429 
cannot restore lysosomal localization or activity of mTORC1 under conditions of amino 430 
acid starvation, although they can restore v-ATPase activity and hence suppress AMPK 431 
activation in low glucose (Figures S7G and S7H). It therefore appears that distinct 432 
accessory factors affect the v-ATPase:Ragulator complex in different ways. Moreover, 433 
our finding of TRPV as an upstream modulator of AMPK may provide new avenues 434 
for identifying drugs that treat related metabolic diseases, and improve physical fitness 435 
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in aged people. 436 
Limitation of Study 437 
In this study, we have shown that in MEFs, as well as in the mouse liver, TRPV channels 438 
function redundantly upstream of the v-ATPase and relay sensing of low glucose/FBP 439 
by aldolase to AMPK activation. Since MEFs and mouse liver are found to express only 440 
TRPV1-4, it therefore remains to be determined if the remaining two members (TRPV5 441 
and 6) play the same role as do the members 1-4 in different tissues. It is also worthy 442 
investigating whether there are other factors augmenting the tethering between the ER 443 
and lysosome and participating in AMPK regulation.  444 
Through utilizing the GCaMP6s-TRPV4 indicator and different dyes for Ca2+ 445 
imaging in different genetic backgrounds, we demonstrated that TRPVs could be 446 
inhibited by the FBP-unoccupied aldolase inside cells. Limitation of current patch 447 
clamping techniques has hindered a direct recording of the inhibition of TRPVs by the 448 
FBP-unoccupied aldolase in low glucose. In addition, as the concentrations of Ca2+at 449 
the ER-lysosome contact fluctuate along with the variation of cellular glucose levels, it 450 
is formally possible that its decrease or increase may have accompanying roles in 451 
modulating other proteins and hence physiological roles beyond the regulation of 452 
AMPK activity. 453 
 454 
STAR METHODS 455 
Detailed methods are provided in the online version of this paper and include the 456 
following: 457 
 KEY RESOURCES TABLE 458 
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 CONTACT FOR REAGENT AND RESOURCE SHARING 459 
 EXPERIMENTAL MODEL AND SUBJECT DETAILS 460 
Mouse Studies 461 
CRISPR Knockout of TRPV1-4 462 
Caenorhabditis elegans Studies 463 
 METHOD DETAILS 464 
Treadmill Endurance Test 465 
Packaging and Injection of Adeno-associated Virus 466 
Plasmids 467 
Cell Culture, Transient Transfection and Lentivirus Infection 468 
Isolation and Culture of Primary Hepatocytes 469 
Immunoprecipitation and Immunoblotting 470 
Quantification of TRPV1-6 Expression Levels by Real-time PCR 471 
Confocal Microscopy 472 
3D-SIM Imaging 473 
STORM Imaging 474 
Intracellular Calcium Measurement by Fura-2-AM 475 
Purification of Lysosomes 476 
Measurement of v-ATPase Activity In Vitro 477 
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Isolation of Light Organelles 478 
In Vitro Reconstitution for Lysosomal Binding Assays 479 
Purification of ER 480 
Protein Production 481 
Kinetic Analysis of CaMKK2 Activity 482 
Analysis of AMP/ATP and ADP/ATP Ratios 483 
Measurement of NAD+ 484 
Determination of Lysosomal Membrane Potential 485 
 QUANTIFICATION AND STATISTICAL ANALYSIS 486 
 DATA AND SOFTWARE AVAILABILITY 487 
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Figure legends 788 
Figure 1. TRPV1-4 Interact with FBP-unoccupied Aldolase and Are Physically 789 
Required for Lysosomal AMPK Activation in Low Glucose 790 
(A) FBP at physiologically relevant concentrations abolishes the interaction between 791 
endogenous TRPV4 and aldolase. Light organelles were prepared from 2-hr glucose-792 
starved MEFs and aliquoted, followed by addition of FBP at concentrations indicated. 793 
Aldolases (represented by ALDOA) were immunoprecipitated, followed by 794 
immunoblotting using the indicated antibodies. Note that the polyclonal antibody raised 795 
in rabbit by His-tagged ALDOA was able to react with all three isozymes of aldolase, 796 
as validated in Figure S1G. The antibody against endogenous TRPV4 was validated in 797 
Figure S1B.  798 
(B) TRPV channels are functionally redundant in mediating AMPK activation under 799 
glucose starvation. TRPV1-/-, TRPV2-/-, TRPV3-/-, TRPV4-/-, TRPV-QKO MEFs, and 800 
wild-type (WT) MEFs as control, were incubated in DMEM with or without 25 mM 801 
glucose for 2 hr, followed by analysis of p-AMPKα and p-ACC. AMPK activation was 802 
virtually abolished in TRPV-QKO MEFs in which no TRPV was detectable by the 803 
antibodies. 804 
(C) FBP dampens the association between endogenous TRPVs and aldolase. Lysates 805 
prepared from 2-hr glucose-starved MEFs were mixed with 10 μM FBP. Aldolase was 806 
immunoprecipitated, followed by immunoblotting using the indicated antibodies. The 807 
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antibody against endogenous TRPV1 was validated in Figure S2B (left panel). 808 
(D) TRPVs are required for inactivation of lysosomal v-ATPase in response to glucose 809 
starvation. TRPV-QKO MEFs were pre-loaded with LysoSensor Green DND-189 and 810 
Hoechst, and were then cultured in DMEM with 25 mM glucose (normal) or DMEM 811 
without glucose (GS) for 2 hr. The relative fluorescent intensities of LysoSensor 812 
(normalized to the intensity of Hoechst) were then analyzed. Results are mean ± SEM; 813 
n value of each group is directly labeled on the bar, and the same below. p value was 814 
determined by Student’s t-test. Representative images of this experiment are shown in 815 
Figure S2D. 816 
(E) TRPVs are required for the lysosomal translocation of AXIN. MEFs were glucose 817 
starved and the localization of AXIN was determined by immunofluorescent staining. 818 
Endogenous AXIN (green, validated previously, (Zhang et al., 2014)) and LAMP2 (red) 819 
were stained with goat anti-AXIN antibody and rat anti-LAMP2 antibody, respectively, 820 
and were imaged by confocal microscopy. “N” indicates nucleus. 821 
(F) TRPV proteins are required for the formation of Ragulator:AXIN:LKB1:AMPK 822 
complex. Endogenous LAMTOR1 in regularly cultured (in DMEM containing 25 mM 823 
glucose) or glucose-starved TRPV-QKO MEFs was immunoprecipitated, followed by 824 
immunoblotting.  825 
(G) TRPVs are required for the activation of AMPK in physiologically low glucose. 826 
TRPV-QKO MEFs were incubated in DMEM containing 1, 3, 5 or 10 mM glucose for 827 
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2 hr, followed by analysis of p-AMPKα and p-ACC. 828 
(H) TRPV channels are specifically involved in the AMPK activation induced by 829 
glucose starvation. TRPV-QKO MEFs, along with its wildtype control, were starved 830 
for glucose (GS) or treated with 1 μM oligomycin, 50 μM dinitrophenol (DTP), 500 831 
μM sorbitol, 1 mM H2O2 or 200 μM A769662, for 2 hr, followed by analysis of p-832 
AMPKα and p-ACC. 833 
(I and J) TRPVs are required for starvation-induced AMPK activation in mouse liver 834 
and primary hepatocytes. TRPV1-/- mice were injected with a combination of AAV-835 
carried siRNAs against TRPV2, TRPV3 and TRPV4. After 4 weeks of injection, p-836 
AMPKα and p-ACC levels in livers from 16-hr starved mice (I) and in hepatocytes 837 
incubated in medium containing 3 mM glucose (resembling the concentration of plasma 838 
glucose detected in 16-hr starved mice, as shown in Figure S2J) for 12 hr (J) were 839 
analyzed. 840 
(K) Requirement of TRPVs for glucose restriction-induced AMPK activation is 841 
conserved in nematodes. Worms (3 days old) of the strain lacking TRPVs (osm-9; ocr-842 
2), along with its wildtype control (N2), were cultured on normal NGM agar or NGM 843 
agar containing 5 mM 2-DG for 20 hr (fed with live OP50 bacteria). The worms were 844 
then lyzed, and the levels of p-AMPKα and p-ACC were determined by 845 
immunoblotting.  846 




See also Figures S1 and S2. 849 
 850 
Figure 2. Glucose Starvation Blocks Ca2+ Channel Activity of TRPVs 851 
(A) Glucose starvation inhibits the activity of TRPV4 channel. A schematic diagram of 852 
the Ca2+ sensor TRPV4-GCaMP6s is shown on the top, and validation of the sensor is 853 
shown in Figures S3A and S3B. MEFs stably expressing TRPV4-GCaMP6s were 854 
treated with glucose-free DMEM, then 5 μM A23187 (at 600 s). The fluorescent images 855 
of TRPV4-GCaMP6s were taken at a regular interval in MEFs after 2 min incubation 856 
with the fresh medium at 37 °C, and the activities of TRPV4, expressed as the change 857 
of fluorescence intensity of GCaMP6s relative to the resting fluorescence intensity 858 
(Δf/f0) were plotted. The changes in fluorescence intensities of the indicator (Δf) were 859 
calculated by subtracting the resting fluorescence intensity of the indicator (f0) from 860 
each value of absolute fluorescent intensity of the indicator (f). Data shown are selected 861 
traces from the 6 cells from 5 dishes/experiments (lower panel). Statistical results were 862 
shown as mean ± SEM; p value by ANOVA. 863 
(B) Summary of the features of TRPV agonists and antagonists. Individual agonists and 864 
antagonists (antag.) along with their cognate TRPV isoforms are tabulated.  865 
 (C) TRPV agonists restore the acidification of lysosomes under glucose starvation. 866 
MEFs pre-loaded with LysoSensor Green DND-189 and Hoechst were glucose starved 867 
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for 2 hr, followed by addition of 50 nM GSK101, 100 nM capsaicin or 0.7 μM RN for 868 
another 15 min. The relative fluorescent intensities of LysoSensor (normalized to the 869 
intensity of Hoechst) were then analyzed. Results are mean ± SEM; p value by ANOVA. 870 
The representative images of this experiment are shown in Figure S3F.  871 
(D) TRPV agonists block glucose starvation-induced AMPK activation. MEFs were 872 
incubated in DMEM with or without 25 mM glucose for 2 hr, then treated with TRPV 873 
agonists as in (C), and analyzed by immunoblotting using the indicated antibodies.  874 
(E) AMG-9810, an antagonist of TRPV1-4, inhibits acidification of lysosomes in 875 
normal glucose. Regularly cultured WT and TRPV-QKO MEFs were treated with 5 μM 876 
AMG-9810 for 30 min, and the pH of lysosome was analyzed as in (C). The 877 
representative images were shown in Figure S4C.  878 
(F) AMG-9810 activates AMPK in a TRPV-dependent manner. Regularly cultured WT 879 
and TRPV-QKO MEFs were treated as in (E), followed by analysis of p-AMPKα and 880 
p-ACC. 881 
(G) AMG-9810 triggers lysosomal translocation of AXIN in normal glucose. Regularly 882 
cultured WT and TRPV-QKO MEFs were treated as in (E), and the lysosomal 883 
translocation of AXIN was determined by immunofluorescent staining as described in 884 
Figure 1E. 885 
Experiments in this figure were performed three times. 886 




Figure 3. TRPVs Maintain a Local Ca2+ in Normal Glucose 889 
(A) Ca2+ releasing-defective TRPV4 mimics glucose starvation causing constitutive 890 
AMPK activation. TRPV-QKO MEFs expressing channel activity-defective HA-891 
tagged TRPV4-D672A, TRPV4-D682A, or WT TRPV4 as a control, were incubated in 892 
DMEM with or without glucose for 2 hr, followed by analysis of p-AMPKα and p-ACC. 893 
(B, C and E) Depletion of Ca2+ by BAPTA-AM, cell-permeable form of the local Ca2+ 894 
chelator BAPTA, triggers the lysosomal AMPK pathway. Regularly cultured MEFs 895 
were treated with 100 μM BAPTA-AM for 30 min, followed by analysis of lysosomal 896 
pH (B; results are shown as mean ± SEM; p value by Student’s t-test), the complex 897 
formation of Ragulator:AXIN:LKB1:AMPK (C), and the lysosomal translocation of 898 
AXIN (E). 899 
(D) BAPTA blocks FBP from dissociating AXIN-LKB1 from LAMTOR1 on light 900 
organelles. Light organelles purified from 2-hr-glucose-starved MEFs were incubated 901 
with 10 μM FBP in the presence or absence of 500 μM BAPTA. Endogenous 902 
LAMTOR1 was then immunoprecipitated, followed by immunoblotting. 903 
(F) BAPTA-AM blocks TRPV agonists-prevented lysosomal dissociation of AXIN. 904 
MEFs were treated as in Figure 2C, except that 100 μM BAPTA-AM was added 905 
together with TRPV agonists.  906 
(G) EGTA-AM (cell-permeable EGTA) that is unable to chelate local Ca2+, cannot 907 
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affect lysosomal pH. Regularly cultured MEFs were treated with 100 μM EGTA-AM 908 
for 30 min, and the pH of lysosome was analyzed. Results are mean ± SEM; p value by 909 
Student’s t-test. 910 
(H) EGTA-AM fails to trigger the lysosomal translocation of AXIN. Regularly cultured 911 
MEFs were treated with 100 μM EGTA-AM for 30 min, and the localization of AXIN 912 
was determined by immunofluorescent staining. 913 
Experiments were performed three times, except (A) twice. 914 
See also Figure S5. 915 
 916 
Figure 4. TRPV Releases Ca2+ Locally from ER to the Space Formed by the 917 
Contact between ER and Lysosome 918 
(A) Glucose starvation does not lead to significant change of global Ca2+. MEFs were 919 
pre-loaded with Fluo-3 and starved for glucose (upper graph, 5 cells), with 100 μM 920 
BAPTA-AM added as a control (lower graph, 6 cells). Statistical results were graphed 921 
as mean ± SEM; p value by Student’s t-test. 922 
(B) STORM images of TRPV4 and LAMP2 in MEFs showing that the two markers are 923 
apposed. HA-TRPV4 (green) and Myc-LAMP2 (red) expressed in TRPV4-/- MEFs 924 
(both expressed at close-to-endogenous levels driven by pBOBI vector) were stained 925 
with rabbit anti-HA antibody and mouse anti-Myc antibody, respectively. The boxed 926 
areas are enlarged on the right side. The proper localization of HA-tagged TRPV4 was 927 
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validated in Figure S5E.  928 
(C) Glucose starvation leads to a decrease of Ca2+ concentration in the vicinity of 929 
lysosomes. MEFs were starved for glucose, and then treated with 5 μM A23187 (at 600 930 
s). Data shown are selected traces from the 5 cells from 2 dishes/experiments. Statistical 931 
results were graphed as mean ± SEM; p value by ANOVA. 932 
(D) TRPV4-released Ca2+ originates from the ER pool. MEFs were treated with 4 μM 933 
thapsigargin for 15 min to deplete the ER Ca2+ pool, or incubated in Ca2+-free DMEM 934 
containing 5 mM EGTA to remove extracellular Ca2+ for 30 min, followed by 935 
determination of the fluorescent signal of the indicator TRPV4-GCaMP6s. Data shown 936 
are selected traces from the 3 cells from 2 dishes/experiments, and were graphed as 937 
mean ± SEM; p value by Student’s t-test. 938 
(E) TRPV4 agonist GSK101 cannot inhibit glucose starvation-induced AMPK 939 
activation in MEFs pre-depleted of the ER pool of Ca2+. MEFs were treated as in (D), 940 
followed by addition of 50 nM GSK101 for another 15 min. Cells were then lyzed, and 941 
p-AMPKα and p-ACC analyzed.  942 
(F) GSK101 inhibits glucose starvation-induced AMPK activation in CaMKK2-/- MEFs. 943 
Cells were incubated in glucose-free medium for 2 hr, followed by addition of 50 nM 944 
GSK101 for another 15 min, and p-AMPKα and p-ACC were analyzed.  945 
(G) TRPV agonists are unable to evoke CaMKK2 signaling. 2-hr glucose-starved MEFs 946 
were treated with 50 nM GSK101, 100 nM capsaicin, 0.7 μM RN, 100 μM carvacrol, 947 
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200 μM 2-APB or 1 μM ionomycin for 15 min and then lyzed. The activity of CaMKK2 948 
was determined by western blotting analysis of the phosphorylation of CaMKI. 949 
(H and I) Activity of v-ATPase in glucose-starved lysosomes can be restored by low 950 
concentration of Ca2+ in vitro. Lysosomes purified from glucose-starved MEFs were 951 
incubated with 0.5 μM CaCl2 and 1 μg of FLAG-TRPV4 (expressed and purified in 952 
HEK293T cells, followed by elution with FLAG epitope peptide). The activity of v-953 
ATPase was determined by its rate to hydrolyze ATP (I) and to transport protons (H). 954 
Results were normalized to the group without CaCl2 added, and are graphed as mean ± 955 
SEM; n = 3 for each condition, p value by Student’s t-test. 956 
Experiments in this figure were performed three times except those in (F) and (G) twice. 957 
See also Figure S5. 958 
 959 
Figure 5. Aldolase Binds to TRPV and Inhibits its Ca2+ Channel Activity in Low 960 
FBP 961 
(A) Aldolases are required for inhibition of TRPV channels. ALDO-TKD MEFs 962 
expressing TRPV4-GCaMP6s were incubated in glucose-free DMEM at 37 °C. After 2 963 
min in the live-cell incubation chamber, the images were captured by confocal 964 
microscopy at a regular interval. After 250 s of starvation, 5 μM AMG-9810 was added 965 
to the medium. The changes of TRPV4 activities were analyzed as described in Figure 966 
2A. n = 3 cells from 2 dishes/experiment, and were graphed as mean ± SEM; p value 967 
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by Student’s t-test. 968 
(B and C) The FBP-constantly-bound aldolase mutant ALDO-D34S fails to block the 969 
activity of TRPV4 in low glucose. MEFs (B) and HEK293T cells (C) expressing 970 
TRPV4-GCaMP6s were incubated in glucose-free DMEM at 37 °C. After 2 min of 971 
incubation in the live-cell incubation chamber, the images were captured by confocal 972 
microscopy at a regular interval. For MEFs, after 350 s of starvation, 5 μM AMG-9810 973 
was added to the medium, and the relative fluorescent intensities were analyzed and 974 
graphed (n = 3 cells from 3 dishes/experiment) in (B). For HEK293T cells expressing 975 
HA-ALDOA or its D34S mutant (red, labelled as #1 and #2 in C), representative images 976 
at t = 0 s and t = 1313 s (for ALDOA) or 1440 s (for ALDOA-D34S) were shown (upper 977 
panel) and the relative fluorescent intensities of GCaMP6s (green) were analyzed and 978 
graphed (lower panel, n = 5 cells from 2 dishes/experiment for ALDOA, and n = 7 cells 979 
from 3 dishes/experiment for ALDOA-D34S) in (C). Statistical analysis results were 980 
shown in mean ± SEM; p value by Student’s t-test. 981 
(D) Schematic illustration of TRPV4 membrane topology. The K535 residue (in red) 982 
of TRPV4 forming the interface for aldolase, and the N-terminal region of aa 1-144 983 
(blue) for binding to v-ATPase (as characterized below) are illustrated.  984 
(E) Glucose starvation fails to inhibit the channel activity of TRPV4-K535A that is 985 
defective in binding to aldolase. Cells were treated and the activity of TRPV4 was 986 
analyzed as in (B), except that TRPV4-GCaMP6s-K535A was expressed in TRPV-987 
QKO MEFs (n = 3 cells from 2 dishes/experiment). Statistical analysis data of (E) were 988 
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shown as mean ± SEM; p value by Student’s t-test. 989 
(F) Re-introduction of TRPV4-K535A to TRPV-QKO MEFs suppresses AMPK 990 
activation under glucose starvation. TRPV-QKO MEFs stably expressing TRPV4-991 
K535A were regularly cultured or glucose starved for 2 hr, followed by analysis of p-992 
AMPKα and p-ACC.  993 
(G) The TRPV4-binding-defective, truncated ALDOA (aa 1-345) fails to trigger 994 
lysosomal AMPK activation. ALDO-TKD MEFs stably expressing ALDOA 1-345 or 995 
WT ALDOA as a control were regularly cultured or glucose starved for 2 hr, followed 996 
by analysis of p-AMPKα, p-ACC. 997 
Experiments were performed for three times. 998 
See also Figure S6. 999 
 1000 
Figure 6. Ca2+ Depletion Reconfigures the Association of Aldolase with v-ATPase 1001 
(A) Knockdown of aldolase bypasses the requirement of TRPV. TRPV-QKO MEFs 1002 
with knockdown of ALDOA-C were regularly cultured, followed by analysis of the 1003 
activation of AMPK. 1004 
(B) Deficiency of TRPV prevents the constitutive activation of AMPK caused by 1005 
ALDO-K230A. TRPV-QKO MEFs expressing HA-TRPV4 or vector as a control were 1006 
infected with lentivirus expressing HA-tagged ALDOA or ALDOA-K230A. Cells were 1007 
regularly cultured, or incubated in glucose-free DMEM for 2 hr, followed by analysis 1008 
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of p-AMPKα and p-ACC.  1009 
(C and D) FBP blocks interaction between aldolase and TRPV, while CaCl2 prevents 1010 
interaction between TRPV with v-ATPase. Lysates from glucose-starved MEFs were 1011 
mixed with 0.5 μM CaCl2 and/or 10 μM FBP. Endogenous aldolase (C) and TRPV4 (D) 1012 
were separately immunoprecipitated, followed by immunoblotting.  1013 
(E) TRPV4 competes the binding of aldolase with v-ATPase in the absence of Ca2+. 1014 
HEK293T cells were transfected with different combinations of Myc-TRPV4 and 1015 
FLAG-ALDOA. Cells were then lyzed, and the protein extracts were mixed with CaCl2 1016 
and FBP, immunoprecipitated with antibody against endogenous ATP6V1B2, and 1017 
followed by immunoblotting.  1018 
(F) Knockout of TRPV renders the interaction of ALDOA-v-ATPase constitutive. 1019 
Experiments were performed as in (C), except that lysates were purified from glucose-1020 
starved TRPV-QKO MEFs.  1021 
(G) TRPV truncation-mutant defective in binding to v-ATPase fails to trigger lysosomal 1022 
AMPK activation. TRPV-QKO MEFs stably expressing HA-tagged Δ1-144-TRPV4 1023 
mutant (unable to bind to v-ATPase, as determined in Figure S7A), were regularly 1024 
cultured or glucose starved for 2 hr, followed by analysis of p-AMPKα and p-ACC. 1025 
(H) The mutant Δ1-144-TRPV4 fails to block v-ATPase activity. Lysosomes purified 1026 
from glucose-starved MEFs were incubated with 0.5 μM CaCl2 and 1 μg of Δ1-144 1027 
mutant of TRPV4. The rate of v-ATPase to hydrolyze ATP was determined. Results 1028 
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were normalized to the group without CaCl2 added, and are graphed as mean ± SEM; 1029 
n = 3 for each condition, p value by Student’s t-test. 1030 
(I) Two-step co-IP shows the co-existence of aldolase, TRPV and v-ATPase 1031 
(represented by its V1A, V1B2, v0d1 and V1D subunits) in the same complex under 1032 
glucose starvation. Complex formations between FLAG-ALDOA, Myc-TRPV4 and 1033 
HA-v-ATPase in glucose-starved HEK293T cells were monitored by two-step co-IP 1034 
followed by immunoblotting.  1035 
 (J) FRET-imaging showing that the lysosomal membrane potential was unchanged 1036 
under glucose starvation. MEFs were cultured in the DMEM containing glucose or not. 1037 
The lysosomal membrane potential was determined by the relative cFRET intensity 1038 
generated from DiBAC4(3)-PE-conjugated Rhodamine pair. n = 4 (normal) and n = 3 1039 
(glucose starved) cells from 2 dishes/experiment. 1040 
Experiments in (G) and (J) were performed twice and others three times. 1041 
See also Figure S7. 1042 
 1043 
Figure 7. Models for the Roles of TRPV in Glucose Sensing and AMPK Activation. 1044 
(A) Inhibition of TRPV efficiently activates AMPK in muscle from aged mice. Mice at 1045 
1.5 year old were intraperitoneally injected with vehicle (10% (w/v) Kolliphor), 30 1046 
mg/kg of A769662, 150 mg/kg of phenformin, or 20 mg/kg of TRPV inhibitor AMG-1047 
9810 (all formulated in the vehicle). One hour after injection, muscles were excised and 1048 
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homogenized, followed by analysis of p-AMPKα and p-ACC levels.  1049 
(B) AMG-9810 has no effect on AMP:ATP and ADP:ATP ratios in muscle. Mice (1.5-1050 
year-old) were treated as in (A), and adenylate nucleotide ratios in muscle tissues were 1051 
measured by CE-MS. Results are mean ± SD; p value by Student’s t-test, n = 3. 1052 
(C) Inhibition of TRPV robustly increases the running capacity of aged mice. Mice 1053 
(1.5-year-old) were intraperitoneally injected with 20 mg/kg AMG-9810 daily for two 1054 
months. The distance (in meters) on the treadmill before exhaustion was graphed. 1055 
Results are mean ± SEM; p value by Student’s t-test, n = 13 for vehicle group and n = 1056 
14 for AMG-9810 group.  1057 
(D) Inhibition of TRPV increases the NAD+ levels in an AMPK-dependent manner. 1058 
Mice (1.5-year-old) were injected with AAV-carried siRNAs against AMPKβ2. After 4 1059 
weeks of injection, mice were intraperitoneally injected with 20 mg/kg AMG-9810 1060 
daily for another three weeks, and the muscular NAD+ levels were measured by HPLC-1061 
MS. Results are mean ± SEM; p value by ANOVA, n = 8 for each group.  1062 
(E) Simplified models depicting how absence of glucose/FBP is sensed and relayed 1063 
from aldolase to TRPVs (TRPV1-4 characterized in MEFs), to v-ATPase, and then to 1064 
the formation of the AXIN-based lysosomal complex for AMPK activation. When 1065 
glucose (Glc) supply is abundant, the FBP-occupied aldolase is associated with v-1066 
ATPase as an integral component for maintaining its activity, and the TRPV channels 1067 
release Ca2+ locally to the ER-lysosome contact site (upper left panel). In low glucose, 1068 
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FBP-unoccupied aldolase interacts with and inhibits the juxtaposed TRPV on the ER 1069 
(upper right panel). After the local Ca2+ dissipates, TRPV becomes accessible to v-1070 
ATPase, thereby re-configuring aldolase:v-ATPase to “sandwich-like” 1071 
aldolase:TRPV:v-ATPase (lower left panel). Subsequently, v-ATPase is inhibited, and 1072 
allows AXIN/LKB1 to bind (Zhang et al., 2014), leading to the formation of the AXIN-1073 
based AMPK-activating complex for AMPK activation by LKB1 (lower right panel). 1074 
Experiments in this figure were performed twice. 1075 
See also Figure S7. 1076 
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KEY RESOURCES TABLE 1077 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit polyclonal antibody against LAMTOR1 (Zhang et al., 2014) N/A 
Rabbit polyclonal antibody against mouse aldolase (Zhang et al., 2017) N/A 
Rabbit anti-phospho-AMPKα-T172 antibody Cell Signaling 
Technology 
cat. #2535; RRID: 
AB_331250  
Rabbit anti-AMPKα antibody Cell Signaling 
Technology 
cat. #2532; RRID: 
AB_330331 
Rabbit anti-AMPKβ2 antibody Cell Signaling 
Technology 
cat. #4148; RRID: 
AB_560862 
Rabbit anti-phospho-ACC-Ser79 antibody Cell Signaling 
Technology 
cat. #3661; RRID: 
AB_330337 
Rabbit anti-ACC antibody Cell Signaling 
Technology 
cat. #3662; RRID: 
AB_2219400 
Rabbit anti-LKB1 antibody Cell Signaling 
Technology 
cat. #3047; RRID: 
AB_2198327 
Rabbit anti-AXIN1 antibody Cell Signaling 
Technology 
cat. #2074; RRID: 
AB_2062419 
Rabbit anti-ALDOA antibody Cell Signaling 
Technology 
cat. #8060; RRID: 
AB_2797635 
Rabbit anti-β-tubulin antibody Cell Signaling 
Technology 
cat. #2128; RRID: 
AB_823664 
Mouse anti-Myc-tag antibody Cell Signaling 
Technology 
cat. #2276; RRID: 
AB_331783 
Mouse anti-phospho-p70S6K-T389 antibody Cell Signaling 
Technology 
cat. #9234; RRID: 
AB_2269803 
Mouse anti-p70S6K antibody Cell Signaling 
Technology 
cat. #9202; RRID: 
AB_331676 
Rabbit anti-mTOR antibody  Cell Signaling 
Technology 
cat. #2983; RRID: 
AB_2105622 
Rabbit anti-T7 tag antibody  Cell Signaling 
Technology 
cat. #13246; RRID: 
AB_2798161 
Rabbit anti-HA tag antibody Cell Signaling 
Technology 
cat. #3724; RRID: 
AB_1549585 
Rabbit anti-PDI antibody Cell Signaling 
Technology 
cat. #3501; RRID: 
AB_2156433 
Rabbit anti-clathrin antibody Cell Signaling 
Technology 




Rabbit anti-N-cadherin antibody Cell Signaling 
Technology 
cat. #13116; RRID: 
AB_2687616 
HRP-conjugated mouse anti-rabbit IgG antibody Cell Signaling 
Technology 
cat. #5127; RRID: 
AB_10892860 
Rabbit anti-TRPV1 antibody Alomone Labs cat. ACC-030; RRID: 
AB_2313819 
Rabbit anti-TRPV4 antibody Alomone Labs cat. ACC-034; RRID: 
AB_2040264 
Rabbit anti-calreticulin antibody Proteintech cat. 27298-1-AP; 
Rabbit anti-ATP6V1B2 antibody Abcam cat. ab73404; RRID: 
AB_1924799 
Rabbit anti-ATP6V1B1 + ATP6V1B2 antibody  Abcam cat. ab200839; 
Rabbit anti-CaMKI antibody Abcam cat. ab68234; RRID: 
AB_1140889 
Rabbit anti-phospho-CaMKI-T177 antibody Abcam cat. ab62215; RRID: 
AB_940775 
Mouse anti-ATP6v0d1 antibody  Abcam cat. ab56441; RRID: 
AB_940402 
Rat anti-LAMP2 antibody  Abcam cat. ab13524; RRID: 
AB_369111 
Rabbit anti-ATP6v0c antibody Novus Biologicals cat. NBP1-59654; 
RRID: AB_11004830 
Anti-flag® M2 affinity gel Sigma cat. A2220; RRID: 
AB_10063035 
Atto 488 goat anti-rabbit IgG antibody Sigma cat. 18772; RRID: 
AB_1137637 
Goat anti-AXIN antibody Santa Cruz 
Biotechnology 
cat. sc-8567; RRID: 
AB_2227789 
Goat anti-TRPV4 antibody Santa Cruz 
Biotechnology 
cat. sc-47527; RRID: 
AB_2256617 
Mouse anti-HA antibody Santa Cruz 
Biotechnology 
cat. sc-7392; RRID: 
AB_627809 
Mouse anti-goat IgG-HRP antibody Santa Cruz 
Biotechnology 
cat. sc-2354; RRID: 
AB_628490 












Alexa Fluor 488 donkey anti-goat IgG antibody  Molecular Probes cat. A11055; RRID: 
AB_2534102 
Alexa Fluor 488 donkey anti-mouse IgG antibody Molecular Probes cat. A21202; RRID: 
AB_141607 
Alexa Fluor 488 donkey anti-rabbit IgG antibody  Molecular Probes cat. A21206; RRID: 
AB_2535792 
Alexa Fluor 568 donkey anti-mouse IgG antibody Molecular Probes cat. A10037; RRID: 
AB_2534013 
Alexa Fluor 568 donkey anti-goat IgG antibody Molecular Probes cat. A11057; RRID: 
AB_142581 
Alexa Fluor 594 donkey anti-rat IgG antibody Molecular Probes cat. A21209; RRID: 
AB_2535795 
Alexa Fluor 594 donkey anti-rabbit IgG antibody Molecular Probes cat. A21207; RRID: 
AB_141637 
Alexa Fluor 594 donkey anti-goat IgG antibody Molecular Probes cat. A11058; RRID: 
AB_2534105 
Alexa Fluor 568 goat anti-rat IgG antibody Molecular Probes cat. A11077; RRID: 
AB_2534121 
Alexa-Fluor 647 donkey anti-mouse IgG antibody Molecular Probes cat. A31571; RRID: 
AB_162542 
Bacterial and Virus Strains  





BL21 Invitrogen cat. C609601 
Cre Recombinase Adenovirus Vector Biolabs cat. 1045 
Chemicals, Peptides, and Recombinant Proteins 
HEPES Gibco cat. 21063 
Polyethylenimine Polysciences, Inc. cat. #23966 
Glucose Sigma cat. G7021 
CaCl2 Sigma cat. C5670 
MnCl2 Sigma cat. 63535 
phosphoenolpyruvate Sigma cat. P7002 
NADH Sigma cat. N8129 
pyruvate kinase Sigma cat. P9136 
lactate dehydrogenase Sigma cat. SAE0049 
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FITC-dextran Sigma cat. FD10S 
Lysosome Isolation Kit Sigma cat. LYSISO1 
Endoplasmic Reticulum Isolation Kit Sigma cat. ER0100 
Capsaicin Sigma cat. 360376 
GSK101 Sigma cat. G0798 
RN-1747 Sigma cat. R1033 
Carvacrol Sigma cat. W224502 
Diazoxide Sigma cat. D9035 
BAPTA-AM Sigma cat. O8001 
BAPTA Sigma cat. A4926 
Ionomycin Sigma cat. I3909 
Oligomycin A Sigma cat. 75351 
2,4-dinitrophenol Sigma cat. 34334 
H2O2 Sigma cat. 323381 
Sorbitol Sigma cat. S6021 
Phenformin Sigma cat. P7045 
Octyl β-D-glucopyranoside Sigma cat. O8001 
Digitonin Sigma cat. D141 
Saponin Sigma cat. S7900 
TritonTM X-100 Sigma cat. T9284 
Conacamycin A Sigma cat. C9705 
DTT Sigma cat. 43815 
MEA Sigma cat. 30070 
Glucose oxidase Sigma cat. G2133 
Catalase Sigma cat. C40 
Imidazole Sigma cat. I5513 
IPTG Sigma cat. I6758 
L-glutathione reduced Sigma cat. G6013 
RPMI 1640 Amino Acids Solution Sigma cat. R7131 
Thapsigargin Sigma cat. T9033 
2-DG Sigma cat. D8375 
Kolliphor P188 Sigma cat. K4894 
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Acetic acid solution Sigma cat. 45754 
Ammonium hydroxide solution Sigma cat. 338818 
Formaldehyde solution Sigma cat. F8775 
FLAG® Peptide Sigma cat. F3290 
Nickel Affinity Gel Sigma cat. P6611 
GSK205 Calbiochem cat. 616522 
AMG-9810 Santa Cruz 
Biotechnology 
cat. sc-201477 
EGTA-AM Santa Cruz 
Biotechnology 
cat. sc-203937 
FBP Santa Cruz 
Biotechnology 
cat. sc-214805 
2-APB Tocris cat. 1224 
A769662 Tocris cat. 3336 
Fura-2-AM Molecular Probes cat. F14185 
Fura-2 Molecular Probes cat. F6799 
CDFA-SE Molecular Probes cat. V12883 
PluronicTM F-127 Molecular Probes cat. P3000MP 
Fluo-3-AM Molecular Probes cat. F14218 
Hoechst Molecular Probes cat. 33342 
LysoSensorTM Green DND-189 Molecular Probes cat. L7535 
SNARFTM-5F Molecular Probes cat. S23923 
CaEGTA stock solution Molecular Probes cat. C3008MP 
ProLong Diamond Antifade Mountant Molecular Probes cat. P36970 
ProLong™ Live Antifade Reagent Molecular Probes cat. P36975 
Ammonium acetate Millipore cat. 5330040050 
Acetonitrile Millipore cat. 1000292500 
RPMI 1640 Medium w/o amino acids US Biological cat. R8999 
TRIzol Invitrogen cat. 15596 
DEPC-treated water Invitrogen cat. AM9922 
RQ1 RNase-free DNase Promega cat. M6101 
GoTaq 1-step RT-qPCR enzyme mix Promega cat. A6020 
RiboLock RNase inhibitor Thermo Fisher cat. E00381 
EZ-Link™ Sulfo-NHS-SS-Biotin Thermo Fisher cat. 21331 
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M-MLV reverse transcriptase Takara cat. 2641A 
Doxycycline Selleckchem cat. S4163 
A-769662 Selleckchem cat. S2697 
Protease inhibitor cocktail Roche cat. 04693116001 
Dulbecco’s modified Eagle’s medium Gibco cat. 11965 
Lipofectamine 2000 Invitrogen cat. 11668-027 
Glucose-free DMEM Gibco cat. 11966 
DMEM without phenol red Gibco cat. 21063 
MEM Amino Acids Solution Gibco cat. 11130-077 
MEM Vitamin Solution Gibco cat. 11120052 
Liver Perfusion Media Gibco cat. 17701 
Liver Digest Buffer Gibco cat. 17703 
William’s medium E Gibco cat. 32551 
Glutamax Gibco cat. 35050 
Sodium pyruvate Gibco cat. 11360 
Glutathione Sepharose 4 Fast Flow Gel GE Healthcare cat. 17-5132 
ACC tide (HMRSSMSGLHLVRRR) GenScript N/A 
Internal standards 1 Human Metabolome 
Technologies 
cat. H3304-1002 
Internal standards 3 Human Metabolome 
Technologies 
cat. H3304-1104 
Critical Commercial Assays 
GoScript Reverse Transcription System Promega Cat. #A5001 
GoTaq qPCR Master Mix Promega Cat. #A6002 
Deposited Data 





Experimental Models: Cell Lines 
Human: HEK293T cells ATCC CRL3216; RRID: 
CVCL_0063 
Human: AD293 (Adeno-X 293) cells Clontech cat. 632271 
54 
  
Mouse: primary hepatocytes from C57BL/6J male mice The Jackson 
Laboratory 
Stock No: 000664 
Black 6 
Experimental Models: Organisms/Strains 
Mouse: LAMTOR1F/F (Zhang et al., 2014) N/A 
Mouse: TRPV1-/- The Jackson 
Laboratory 
Dr. David Julius; 
RRID: MGI:4417977 
Mouse: CaMKK2-/- The Jackson 
Laboratory 
Dr. Talal Chatila; 
RRID: MGI:4941485 
Mouse: LKB1F/F Frederick National 
Laboratory for Cancer 
Research 
Dr. Ron DePinho; 
RRID: MGI:5659884 
















siRNA targeting sequence: mAldoa (#1): 5’- 
CCAAGTGGCGCTGTGTGCT-3′ 
(Zhang et al., 2017) N/A 
siRNA targeting sequence: mAldob (#1): 5’-
GCTCTCTGAGCAGATCCAT-3′ 
(Zhang et al., 2017) N/A 
siRNA targeting sequence: mAldoc (#1): 5’ -
GAGTCTAGAGCTTATGTCT-3′ 
(Zhang et al., 2017) N/A 
siRNA targeting sequence: mTrpv2: 5’-
GGTGCTTCAGGGTGGAGGAAG-3’ 
This paper N/A 
siRNA targeting sequence: mTrpv3: 5’-
GGAGAACGTCTCCAAAGAAAG-3’ 
This paper N/A 
siRNA targeting sequence: mTrpv4: 5’-
GACATCCCTGCACATTGCCAT-3’ 
This paper N/A 
siRNA targeting sequence: mAMPKβ2: 5’- 
CTCATCTGCAATCAAATGC-3’ 
This paper N/A 
sgRNA targeting sequence: mTrpv1: 5’-
GGAGTCGCACCCGGCTTTTT-3’ 
http://crispr.mit.edu N/A 





sgRNA targeting sequence: mTrpv2: 5’-
CGGTCACGGTCAAACCGATT-3’ 
http://crispr.mit.edu N/A 
sgRNA targeting sequence: mTrpv2: 5’-
GGTACTTGCTGGTCCGGCGC-3’ 
http://crispr.mit.edu N/A 
sgRNA targeting sequence: mTrpv3: 5’-
AGTACAACAGGGTTCCCGCC-3’ 
http://crispr.mit.edu N/A 
sgRNA targeting sequence: mTrpv3: 5’-
ATCTTCGCGGCTGTGTCCGA-3’ 
http://crispr.mit.edu N/A 
sgRNA targeting sequence: mTrpv4: 5’-
TGTCGTTGCGCCCG TTGCTT-3’ 
http://crispr.mit.edu N/A 
sgRNA targeting sequence: mTrpv4: 5’-
GTAAGTGCCGTAGTCGAACA-3’ 
http://crispr.mit.edu N/A 
Primer: 5’-CCGGCTTTTTGGGAAGGGT-3’ and 5’-





Primer: 5’-GGACCCAAATCGGTTTGACC-3’ and 5’-





Primer: 5’-ACGGTCACCAAGACCTCTC-3’ and 5’-





Primer: 5’-AAACCTGCGTATGAAGTTCCAG-3’ and 5’-





Primer: 5’-TGCTG CTATAATGCTGATGGAG-3’ and 5’- 





Primer: 5’-GACCAGACACCTGTAAAGGAAC-3’ and 5’-






CMV-GCaMP6s Addgene plasmid #40753 
LentiCRISPR v2 Addgene plasmid #52961 
pLL3.7 vector Adegene plasmid #11795 
pcDNA3.3 vector Thermo Fisher cat. K830001 
pBOBI vector (Miyoshi et al., 1998) N/A 
pLVX-IRES vector Takara cat. 631849 
AAV2 inverted terminal repeat (ITR) vectors pseudo-
typed with AAV9 capsid 
(Bish et al., 2008) N/A 
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pET-28a Novagen cat. 70777 
pGEX4T-1 GE Healthcare cat. 28-9545-49 
Software and Algorithms 
StepOne software version 2.3 Applied Biosystems https://www.thermofi
sher.com 
Zen 2012 Zeiss https://www.zeiss.co
m 
DeltaVision OMX system GE Healthcare https://www.gelifesci
ences.com 
NIS Elements software with STORM package version 
4.30 build 1053 
Nikon https://www.nikon.co
m 
Qualitative Analysis B.06.00 Agilent https://www.agilent.c
om 
SPSS Statistics 17.0 IBM https://www.ibm.com 
GraphPad Prism 6 Graphpad https://www.graphpa
d.com 
Imaris 7.4.0 Bitplane https://www.bitplane.
com 





CONTACT FOR REAGENT AND RESOURCE SHARING 1079 
Requests for reagents and resources should be directed to and will be fulfilled by the Lead 1080 
Contact, Sheng-Cai Lin (linsc@xmu.edu.cn). 1081 
EXPERIMENTAL MODEL AND SUBJECT DETAIL 1082 
Mouse Studies 1083 
Protocols for all animal experiments were approved by the Institutional Animal Care and the 1084 
Animal Committee of Xiamen University. Mice were housed with free access to water and 1085 
standard diet (65% carbohydrate, 11% fat, 24% protein). The light was on from 8 a.m. to 8 p.m. 1086 
Male littermate controls were used throughout the study. 1087 
CRISPR Knockout of TRPV1-4  1088 
The genes (mTrpv1, mTrpv2, mTrpv3, and mTrpv4) were deleted from MEFs using the 1089 
CRISPR-Cas9 system. Nucleotides were annealed to their complements containing the cloning 1090 
tag aaac, and inserted into the back-to-back BsmBI restriction sites of lentiCRISPRv2 vector. 1091 
The four constructs were then separately subjected to lentivirus packaging using HEK293T 1092 
cells in which cells were transfected with 2-3 µg of DNA in Lipofectamine 2000 transfection 1093 
reagent per well of a 6-well plate. At 30 hr post transfection, the four kinds of virus were collected 1094 
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and then added in 1:1:1:1 ratio to MEFs (cultured to 15% confluence) for another 72 hr-infection. 1095 
When cells were approaching to confluency, they were single-cell sorted into 96-well dishes. 1096 
Clones were expanded and evaluated for knockout status by sequencing. 1097 
Caenorhabditis elegans Studies 1098 
Worms were maintained on nematode growth medium (NGM) plate with OP50 as standard 1099 
food (Brenner, 1974). All worms were cultured at 20 °C. The osm-9(ky10); ocr-2(ak47) strain 1100 
was obtained by crossing osm-9(ky10); ocr-2(ak47); ocr-1(ak46) strain (FG125) with N2, and 1101 
outcrossed 6 times to N2 prior to the experiment. Glucose restriction was performed as 1102 
described previously (Schulz et al., 2007). Plates used for the treatment of glucose restriction 1103 
were prepared from the same batch of NGM agar as the control plates. 1104 
 1105 
METHOD DETAILS 1106 
Treadmill Endurance Test 1107 
The treadmill endurance test was performed as described previously (Park et al., 2017), with 1108 
minor modifications. Briefly, test was performed during dark cycle. Mice were trained on Rodent 1109 
Treadmill NG (UGO basile, cat. 47300) at 10 m/min for 5 min for 2 days. For the treadmill 1110 
endurance test, the treadmill was set at a 15° incline, and the speed of treadmill was set to 1111 
increase in a ramp-mode (10 m/min for 10 min followed by an increase to final speed of 18 1112 
m/min within 15 min). The test was terminated when mice reached exhaustion, which was 1113 
defined as staying immobilized after 30 s of electric shocks (2 Hz, 0.5 mA). 1114 
Packaging and Injection of Adeno-associated Virus 1115 
Adeno-associated virus (AAV) was packaged in HEK293T cells following the protocol from 1116 
Grieger et al. (2006). Briefly, cells used for in-house viral production were maintained in 150-1117 
mm dishes. Some 7 μg of pAAV-RC2/9 (AAV2 inverted terminal repeat (ITR) vectors pseudo-1118 
typed with AAV9 capsid) plasmid, 21 μg of pAAV-helper plasmid, and 7 μg of pAAV2 plasmid 1119 
(carrying siRNAs against mouse TRPV2 to TRPV4) were added to 4 mL of DMEM without 1120 
phenol red (Gibco, cat. 21063), followed by mixing with 175 μL of polyethylenimine (PEI) 1121 
solution (1 mg/mL, pH 7.5). The mixture was then incubated at room temperature for 20 min, 1122 
and then added to the dishes. 60 hr post transfection, cells were harvested by scraping and 1123 
centrifugation. The viral particles were purified from the pellet by an Optiprep gradient as 1124 
described previously (Grieger et al., 2006). Purified AAV was titered by real-time qPCR (RT-1125 
qPCR), and then stored at - 80 °C. 1126 
AAV was delivered to 6 week old male TRPV1-/- mice intravenously via lateral tail vein injection. 1127 
For each mouse, 1× 1011 particles of virus, adjusted to 200 μL final volume (with PBS, pH7.4), 1128 
was injected. Four weeks post injection, liver tissues were dissected and analysis for AMPK 1129 
activation. 1130 
Plasmids 1131 
Point mutations of human ALDOA, mouse TRPV1 and human TRPV4 were performed by a 1132 
PCR-based site-directed mutagenesis method using PrimeSTAR HS polymerase (Takara). 1133 
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Expression plasmids for various proteins were constructed in the pcDNA3.3 vector for transient 1134 
transfection, in pBOBI for lentivirus packaging (stable expression), or in pLVX-IRES for 1135 
doxycycline-inducible expression. PCR products were verified by sequencing (Invitrogen, 1136 
China). The lentivirus-based vector pLL3.7 was used for expression of siRNA in HEK293T and 1137 
mouse embryonic fibroblasts (MEFs), and the AAV-based vector pAAV2 for mouse liver. 1138 
Cell Culture, Transient Transfection and Lentivirus Infection 1139 
HEK293T, AD293 (Adeno-X 293) cells and MEFs were maintained in Dulbecco’s modified 1140 
Eagle’s medium supplemented with 10% fetal bovine serum (FBS), 100 IU penicillin, 100 1141 
mg/mL streptomycin at 37 °C in a humidified incubator containing 5% CO2. PEI at a final 1142 
concentration of 10 μM was used to transfect HEK293T cells. Total DNA for each plate was 1143 
adjusted to the same amount by using relevant empty vector. Transfected cells were harvested 1144 
at 24 hr after transfection. Lentivirus for infection of MEFs was packaged in HEK293T cells by 1145 
transfection using Lipofectamine 2000. At 30 hr post transfection, medium was collected and 1146 
added to the cells. The cells were incubated for another 24 hr. Adenovirus was propagated in 1147 
AD293 cells and purified by cesium chloride density gradient ultracentrifugation. LAMTOR1F/F, 1148 
and CaMKK2-/- MEFs were established by introducing SV40 T antigen into primary cultured 1149 
embryonic cells from a litter of corresponding mice. LAMTOR1-/- MEFs were generated by 1150 
infecting LAMTOR1F/F MEFs with adenoviruses expressing the Cre recombinase for 12 hr. The 1151 
infected cells were then incubated in the fresh DMEM for another 8 to 10 hr before further 1152 
treatments. Cells were verified to be free of mycoplasma contamination and authenticated by 1153 
STR sequencing. ALDO-TKD MEFs were generated and validated as described previously 1154 
(Zhang et al., 2017). In brief, MEFs carrying doxycycline-inducible expression of ALDOA-C 1155 
(infected with lentivirus packaged with pLVX-IRES-ALDOA, pLVX-IRES-ALDOB and pLVX-1156 
IRES-ALDOC) were cultured in medium containing doxycycline (Dox, 100 ng/mL), and were 1157 
infected with lentivirus expressing siRNA against ALDOA, ALDOB and ALDOC sequentially, or 1158 
GFP siRNA as a control, followed by incubation in doxycycline-free medium for another 12 hr. 1159 
For glucose starvation, cells were rinsed twice with PBS, and then incubated in glucose-free 1160 
DMEM supplemented with 10% FBS and 1 mM sodium pyruvate for desired periods of time at 1161 
37 °C. For depletion of extracellular Ca2+, cells were incubated in a solution containing all 1162 
components (except CaCl2) of DMEM without phenol red (Gibco cat. 21063) and supplemented 1163 
with sodium pyruvate and 5 mM EGTA for desired time periods at 37 °C. 1164 
Isolation and Culture of Primary Hepatocytes 1165 
Primary hepatocytes were isolated from mice with a modified two-step perfusion method using 1166 
Liver Perfusion Media and Liver Digest Buffer. Cells were plated in collagen-coated 6-well 1167 
plates in William’s medium E plus 10% FBS, 100 IU penicillin and 100 mg/mL streptomycin. 1168 
After 4 hr of attachment, the medium was replaced with fresh William’s medium E with 1% BSA 1169 
for further use. 1170 
Immunoprecipitation and Immunoblotting 1171 
Endogenous LAMTOR1, TRPV4, and aldolase were immunoprecipitated and analyzed as 1172 
described previously (Zhang et al., 2014) with minor modifications. Briefly, 10 × 15 cm dishes 1173 
of MEFs (grown to 80% confluence) for IP of LAMTOR1; 8 × 15 cm dishes of MEFs (grown to 1174 
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80% confluence) for IP of TRPV4 and aldolase for each gel lane were collected and lysed with 1175 
750 μL/dish of ice cold ODG buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1 mM EDTA (not 1176 
included in assays involving Ca2+ addition)), 2% ODG, 5 mM β-mercaptoethanol with protease 1177 
inhibitor cocktail], followed by sonication and centrifugation at 4 °C for 15 min. Cell lysates were 1178 
incubated with respective antibodies overnight. Overnight protein aggregates were pre-cleared 1179 
by centrifugation at 20,000 g for 10 min, and protein A/G beads (1:250, balanced with ODG 1180 
buffer) were then added into the lysate/antibody mixture for another 3 hr at 4 °C. The beads 1181 
were spun and washed with 100 times volume of ODG buffer for 3 times at 4 °C and then mixed 1182 
with an equal volume of 2× SDS sample buffer and boiled for 10 min before immunoblotting. 1183 
For IP of ectopically expressed TRPV or aldolase, FLAG-tagged TRPV and aldolase or HA-1184 
tagged aldolase and TRPV were co-transfected into a 10 cm-dish of HEK293T cells. After 24 1185 
hr of transfection, cells were collected and lysed in 600 µL of ice cold ODG buffer, followed by 1186 
sonication and centrifugation at 4 °C for 15 min. ANTI-FLAG® M2 Affinity Gel (1:100, balanced 1187 
in ODG buffer) was added into the lysates and mixed for 4 hr at 4 °C. The beads were washed 1188 
with 200 times volume of ODG buffer for 3 times at 4 °C. The FLAG tagged TRPV and aldolase 1189 
were then eluted with 30 µL of FLAG® Peptide (400 µg/mL final concentration) for another 45 1190 
min at 4 °C. Some 30 µL of eluent was then collected, mixed with 7.5 µL of 5× SDS buffer, and 1191 
boiled for 10 min before immunoblotting. In particular, samples containing TRPV2 were not 1192 
boiled to avoid the formation of insoluble aggregates that would fail to run into the SDS-PAGE. 1193 
To analyze the levels of p-AMPKα and p-ACC in MEFs, cells grown to 70-80% confluence in a 1194 
well of a 6-well dish were lysed with 250 μl of ice cold lysis buffer (20 mM Tris-HCl, pH 7.5, 150 1195 
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM 1196 
β-glycerolphosphate, with protease inhibitor cocktail). The lysates were then centrifuged at 1197 
20,000 g for 10 min at 4 °C and an equal volume of 2× SDS sample buffer was added into the 1198 
supernatant. To analyze the levels of p-AMPKα and p-ACC in liver, freshly excised tissue was 1199 
added with ice-cold lysis buffer (10 μL/mg liver weight), followed by homogenization and 1200 
centrifugation as described above. The lysates were then mixed with 2× SDS sample buffer 1201 
and subjected to immunoblotting. To analyze the levels of p-AMPKα and p-ACC in nematodes, 1202 
about 150 nematodes cultured on the NGM agar plate were collected for each sample. Worms 1203 
were washed with ice-cold M9 buffer (22.1 mM KH2PO4, 46.9 mM Na2HPO4, 85.5 mM NaCl, 1204 
and 1 mM MgSO4) and were lyzed with 150 μL of ice-cold lysis buffer. The lysates were then 1205 
mixed with 5× SDS sample buffer, followed by homogenization and centrifugation as described 1206 
above, and then subjected to immunoblotting. Levels of total proteins and phosphorylated 1207 
proteins were analyzed on separate gels, and representative immunoblots were shown. The 1208 
band intensities on developed films were quantified using Image J software (National Institutes 1209 
of Health Freeware). 1210 
Quantification of TRPV1-6 Expression Levels by Real-time PCR 1211 
To isolate total RNA, a 10 cm-dish of MEFs or 10 mg of mouse liver were lysed in 1 mL of 1212 
TRIzol reagent, followed with addition of 270 µL of chloroform and mixed vigorously. After 1213 
centrifugation at 12,000 g for 15 min at 4 °C, 550 µL of upper aqueous layer was transferred to 1214 
a clean tube. RNA was then precipitated by adding 670 µL of isopropanol, followed with 1215 
centrifugation at 12,000 g for 10 min at 4 °C. The pellet was washed with 75% ethanol for 3 1216 
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times by centrifugation at 7,500 g for 5 min, and was dissolved with 30 µL of DEPC-treated 1217 
water. The concentration of RNA was then determined by a NanoDrop 2000 spectrophotometer 1218 
(Thermo Scientific). Some 5 µg of RNA was digested with RQ1 DNase (supplemented with 1219 
RiboLock RNase inhibitor) for 30 min at 37 °C, and at 68 °C for another 10 min. The digested 1220 
RNA was mixed with random primers at 70 °C for 10 min, and chilled on ice immediately. dNTP 1221 
and M-MLV reverse transcriptase was then added to the mixture, followed by incubation at 1222 
30 °C for 10 min, 42 °C for 1 hr, and 70 °C for 15 min.  1223 
The annealing temperature of each pair of primers was first optimized according to the 1224 
amplification curves, melting curves, and bands on agarose gel of serial pilot reactions (in which 1225 
a serial annealing temperature was set according to the estimated annealing temperature of 1226 
each primer pair). Here, all annealing temperatures were set at 60 °C. The standard curve used 1227 
for quantifying the absolute copy number of each TRPV was then generated by using serial 1228 
dilutions of pcDNA3.3 plasmids containing cDNA of each TRPV (as a template), during which 1229 
the optimal threshold was set automatically. The correlation coefficient (R2) of each standard 1230 
curve was calculated. Here, all R2 values were larger than 0.99. The absolute copy number of 1231 
each TRPV was then determined according to the standard curves generated from the same 1232 
assay plate. In experiments described above, GoTaq 1-step RT-qPCR enzyme mix was used 1233 
for amplifying targets; the StepOnePlus system and StepOne software version 2.3 (Applied 1234 
Biosystems) were used for performing PCR assays and data processing. 1235 
Confocal Microscopy 1236 
For fixed cell samples, the slides were fixed for 20 min with 4% formaldehyde in phosphate-1237 
buffered saline (PBS) at room temperature. The slides were rinsed twice with PBS and cells 1238 
were permeabilized with 0.05% Triton X-100 in PBS (except for staining AXIN with 0.1% Triton 1239 
X-100) for 5 min at 4 °C. After rinsing twice with PBS, the slides were incubated with primary 1240 
antibody diluted in PBS overnight at 4 °C. Here, goat anti-AXIN, rabbit anti-ATP6V1B1 + 1241 
ATP6V1B2, anti-mTOR, rabbit anti-T7 tag, mouse anti-ATP6v0d1 and rat anti-LAMP2 were 1242 
used, as described in the corresponding legend to specific figures. The cells were then rinsed 1243 
three times with 1 mL of PBS, and then incubated with secondary antibody for 8 hr at room 1244 
temperature in the dark. The Alexa Fluor 405 goat anti-rabbit IgG, Alexa Fluor 488 donkey anti-1245 
goat IgG, Alexa Fluor 488 donkey anti-mouse IgG, Alexa Fluor 488 donkey anti-rabbit IgG, 1246 
Alexa Fluor 568 donkey anti-mouse IgG, Alexa Fluor 568 donkey anti-goat IgG, Alexa Fluor 594 1247 
donkey anti-rat IgG, Alexa Fluor 594 donkey anti-rabbit IgG, and Alexa Fluor 594 donkey anti-1248 
goat IgG antibodies were used, as described in the corresponding legends. Cells were washed 1249 
for another 4 times with 1 mL of PBS, and then mounted on slides using ProLong Diamond 1250 
Antifade Mountant. Confocal microscopic images were taken on a Zeiss Laser Scanning 1251 
Microscope (LSM) 780 with a 63× 1.4 NA oil objective. 1252 
For detecting the pH of lysosomes, MEFs were grown on 35 mm of glass-bottom dishes, and 1253 
were cultured to 60–80% confluence. Cells were treated with 1 μM (final concentration) 1254 
LysoSensor™ Green DND-189 for 1 hr, then washed twice with PBS and incubated in fresh, 1255 
desired medium for another 30 min. In the meantime, 2 μg/mL (final concentration) Hoechst 1256 
was added into the medium for staining nucleus before taking images. For detecting the 1257 
cytosolic pH, MEFs were incubated with 10 μM (final concentration) SNARFTM-5F in serum-free 1258 
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DMEM for 0.5 hr, washed twice with PBS and then switched to glucose-free DMEM containing 1259 
10% FBS. For recording the signals of Fluo-3 in real time, cells were loaded with 5 μM (final 1260 
concentration) Fluo-3-AM for 30 min, then washed twice with PBS and incubated in fresh, 1261 
desired medium for another 30 min. Before image taking, ProLong™ Live Antifade Reagent 1262 
was added to the medium. MEFs expressing GCaMP6s-fused protein were directly imaged 1263 
after adding ProLong™ Live Antifade Reagent to the medium. During imaging, live cells were 1264 
kept at 37 °C, 5% CO2 in a humidified incubation chamber (ZEISS, Incubator PM S1). Images 1265 
were taken on a Zeiss LSM 780 with a 63× 1.4 NA oil objective at regular intervals. The objective 1266 
lens was automatically focused at every 30 s. 1267 
In experiments described above, fluorescent dye Alexa Fluor 405 and Hoechst were excited 1268 
with a Diode laser using a 405-nm laser line; Lysosensor, Fluo-3, GCaMP6S, SNARFTM-5F and 1269 
Alexa 488 with an Ar gas laser (laser module LGK 7812) using a 488-nm laser line; Alexa 568 1270 
with a DP Solid State laser (YLK6120T) using a 561-nm laser line; Alexa 594 with a HeNe gas 1271 
laser (LGK 7512 PF) using a 594-nm laser line; and Alexa 647 with a HeNe gas laser (LGK 1272 
7628-1F) using a 633 nm laser line. The parameters, including ‘PMT voltage’, ‘Offset’, ‘Pinhole’ 1273 
and ‘Gain’, were kept unchanged between each picture taken. The resolution of image is 1,024 1274 
× 1,024 pixels.  1275 
For imaging endogenous ER-localized TRPV4, the Semi-intact IF protocol (Du et al., 2016) was 1276 
used. MEFs were grown on a 35 mm dish (In Vitro Scientific, cat. D35-20-10-N) to 50-60% 1277 
confluence. Cells were rinsed with PBS once, and treated with Buffer I (25 mM HEPES, pH 7.2, 1278 
125 mM potassium acetate, 5 mM magnesium acetate, 1 mM DTT, 1 mg/L glucose and 25 1279 
μg/mL digitonin) for 2 min on ice, and then Buffer II (25 mM HEPES, pH 7.2, 125 mM potassium 1280 
acetate, 5 mM magnesium acetate, 1 mM DTT and 1 mg/L glucose) for another 15 min on ice. 1281 
The cells were then treated with 4% formaldehyde in PBS at room temperature for 10 min. The 1282 
slides were rinsed twice with PBS and cells were then permeabilized with 0.05% Triton X-100 1283 
in PBS for 5 min at 4 °C. After rinsing twice with PBS, the slides were blocked in Block Buffer 1284 
(10% FBS in PBS, with 0.1% saponin) for 30 min. The slides were washed twice with PBS and 1285 
incubated with primary antibodies (goat anti-TRPV4 and rat anti-LAMP2) diluted in Block Buffer 1286 
overnight at 4 °C. The cells were then rinsed three times with PBS, and then incubated with 1287 
secondary antibodies (Alexa Fluor 488 donkey anti-goat IgG and Alexa Fluor 594 donkey anti-1288 
rat IgG) for another 8 hr at 4 °C in the dark, followed by washing for four times with PBS and 1289 
then mounted on slides using ProLong Diamond Antifade Mountant. The slides were imaged 1290 
on a Zeiss Laser Scanning Microscope (LSM) 800 using an AiryScan detector. The fluorescent 1291 
dye Alexa Fluor 488 was excited with a Diode laser using a 488-nm laser line, and Alexa Fluor 1292 
640 with a Diode laser using a 640-nm laser line. Images were processed in AiryScan mode on 1293 
Zen 2012 software. The resolution of images is 2,312 × 2,312 pixels. 1294 
3D-SIM Imaging 1295 
MEFs stably expressing HA-TRPV4 were grown in a 35-mm dish (In Vitro Scientific, cat. D35-1296 
20-10-N) to 50-60% confluence, and were treated following the Semi-intact IF protocol as 1297 
described above, except that the cells were incubated in rabbit anti-HA tag and rat anti-LAMP2 1298 
primary antibodies, and then with Alexa Fluor 488 donkey anti-rabbit IgG and Alexa Fluor 568 1299 
goat anti-rat IgG secondary antibodies. Images were acquired using a UPlanSApochromat 1300 
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100× 1.4NA, oil immersion objective lens (Olympus) and a back-illuminated Cascade II 512 × 1301 
512 electron-multiplying charge-coupled device (EMCCD) camera (Photometrics) on an OMX 1302 
version 2 system (Applied Precision) equipped with 405-, 488-, 561-, and 647 nm solid-state 1303 
lasers. Immersion oil of refractive index 1.1515 was used, after being empirically determined to 1304 
give the most symmetric point spread function. Samples were illuminated by a coherent 1305 
scrambled laser light source that had passed through a diffraction grating to generate the 1306 
structured illumination by interference of light orders in the image plane to create a 3D 1307 
sinusoidal pattern, with lateral stripes approximately 0.2 μm apart. The pattern was shifted 1308 
laterally through five phases and through three angular rotations of 60º for each Z-section, 1309 
separated by 0.125 μm, and the range of z-stack was 3 μm. The power of each laser was 1310 
adjusted to achieve optimal intensities of between 2,000 and 4,000 counts in a raw image of 1311 
16-bit dynamic range, at the lowest possible laser power to minimize photo bleaching. Each 1312 
frame acquisition was separated by a 300-ms pause. Raw images were processed and 1313 
reconstructed as described previously (Schermelleh et al., 2008). The channels were then 1314 
aligned in x, y, and rotationally using predetermined shifts as measured using a target lens and 1315 
the Softworx alignment tool (Applied Precision). The images were further processed in OMX 1316 
system (Applied Precision). 1317 
STORM Imaging 1318 
MEFs stably expressing HA-TRPV4 and Myc-LAMP2 were cultured in the Lab-Tek™II 1319 
chambered #1.5 German Coverglass System (NUNC, 155409, 8 Chamber) to 50% confluence, 1320 
and were treated following the Semi-intact IF protocol as described above, except that the cells 1321 
were incubated in rabbit anti-HA tag primary antibody and mouse anti-Myc tag primary antibody, 1322 
and then with the Atto 488 goat anti-rabbit IgG and Alexa-Fluor 647 donkey anti-mouse IgG 1323 
secondary antibodies. The slides were then fixed with 4% formaldehyde for another 10 min, 1324 
and washed twice with PBS. The STORM Imaging Buffer with MEA was then prepared 1325 
according to the manufacturer’s instructions. Briefly, 7 μL of GLOX (14 mg of glucose oxidase, 1326 
50 μL catalyze (17 mg/mL), 200 μL Buffer A (10 mM Tris, pH 8.0, and 50 mM NaCl), vortexed 1327 
to dissolve and cooled on ice) and 70 μL 1 M MEA (77 mg MEA dissolved in 1.0 mL of 0.25 N 1328 
HCl) were added to 620 μL Buffer B (50 mM Tris, pH 8.0, 10 mM NaCl and 10% (m/v) glucose) 1329 
in a 1.5 mL Eppendorf tube, followed by gentle vortex. The mixture was then added to each 1330 
well, and images were taken on an N-STORM (Nikon). The imaging was performed using an 1331 
inverted microscope system (Ti-E Perfect Focus; Nikon) equipped with a monolithic laser 1332 
combiner (MLC400, Agilent Technologies) containing solid-state lasers of wavelengths 405 nm, 1333 
488 nm, and 561 nm at 50 mW (maximum fiber output power) and a 647-nm laser at 125 mW. 1334 
After locating a suitable field, a diffraction-limited TIRF image was acquired for reference, 1335 
followed by a STORM acquisition. The 647-nm laser was then sequentially fired at 100% power 1336 
to excite all possible fluorophore molecules and photoswitch them into a nonemitting dark state, 1337 
and then the 488-nm laser. The emitted wavelengths from Alexa Fluor 647 and Atto 488 1338 
fluorophores were then sequentially collected by the plan-Apochromat 100×/1.49 TIRF 1339 
objective (Nikon), filtered by an emission filter set (Nikon TIRF Cube consisting of a TRF89902-1340 
EM filter set, Chroma Technology), and detected on an electron-multiplying charge-coupled 1341 
device camera (Ixon DU-897, Andor Technology). During imaging, 20,000 sequential frames of 1342 
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each channel were acquired. The image acquisition, lateral drift correction, and data processing 1343 
were performed by using NIS Elements software with STORM package (version 4.30 build 1053, 1344 
Nikon) as described previously (Dempsey et al., 2011; Jones et al., 2011).  1345 
Intracellular Calcium Measurement by Fura-2-AM 1346 
The average concentration of TRPV-mediated, localized calcium, [Ca2+]l , in the vicinity of 1347 
lysosomes was estimated according to the amount of TRPV-released, lysosome-surrounded 1348 
calcium ions and the total volume of TRPV-lysosome contact site. Briefly, MEFs were cultured 1349 
to 80-90% confluence in a black, clear-bottom 96-well assay plate (Corning, cat. 3603). Cells 1350 
were cultured in DMEM without phenol red supplemented with sodium pyruvate, then loaded 1351 
with 5 μM (final concentration, pre-mixed with the PluronicTM F-127 stock solution at a ratio of 1352 
1:1) Fura-2-AM for 1 hr. The unloaded Fura-2-AM was then removed by two times of PBS 1353 
rinsing, and the cells were further incubated in DMEM without phenol red (supplemented with 1354 
sodium pyruvate) for 0.5 hr. The average concentrations of intracellular calcium, [Ca2+]i, were 1355 
then determined according to the fluorescent intensities of Fura-2 excited at 340 nm (Fλ1, 1356 
represents Ca2+ bound-state) and 380 nm (Fλ2, represents Ca2+ unbound-state), respectively 1357 




   1359 





 Q and 𝐾
d (for Fura-2) were obtained by a in situ calibration assay (Petr and Wurster, 1361 
1997). This assay was also used for correcting background fluorescence of the Fura-2 indicator. 1362 
Briefly, a series of solutions containing different concentrations of calcium ions were first 1363 
prepared by diluting the CaEGTA stock solution at 37 °C, pH 7.2, mimicking the in vivo situation. 1364 
The solution, along with 10 μM ionomycin, was then added to the Fura-2-loaded MEFs. 1365 
Following the measurement of the Fλ1 and Fλ2 of Fura-2, cells were incubated for an additional 1366 
20 min with 6 mM MnCl2 to quench the fluorescence of the indicator. The remaining 1367 
fluorescence was considered as background fluorescence, which was subtracted from the total 1368 
fluorescence, afterwards. The difference between the total fluorescence and the background 1369 
fluorescence was considered as the actual cytosolic fluorescence. The corrected values of Fλ1 1370 
were increased proportionally to the increase of Ca2+ concentrations in CaEGTA solutions, while 1371 
the corrected values of Fλ2 were changed independent of Ca2+ concentrations. The value of 𝑅min, 1372 
was generated from the corrected Fλ1/Fλ2 ratio at zero free Ca2+, and 𝑅max from 27.96 μM 1373 
(saturating) Ca2+. Q value was determined by the ratio of Fλ2 at zero free Ca2+, to Fλ2 at 27.96 1374 




 - 𝑅) × Q], generated from each solution, were 1375 
then plotted with the log value of its free Ca2+ concentration. After that, a straight line was 1376 
yielded, and a linear regression equation: y = 1.2956x + 8.7237 (R2 = 0.935), was generated. 1377 
The log of 𝐾
d
 was determined according to the x-intercept of this straight line. We determined 1378 
that the 𝐾
d for Fura-2 is 184.7872 nM. 1379 
Purification of Lysosomes 1380 
Lysosomes were purified by Lysosome Isolation Kit according to the manufacturer’s instructions, 1381 
with minor modifications. Briefly, MEFs from sixty 10-cm dishes (60-80% confluence) were 1382 
64 
  
collected by directly scrapping at room temperature, followed by centrifugation for 5 min at 500 1383 
g at 37 °C. Cells were resuspend in 7 mL of 1× Extraction Buffer containing protease inhibitor 1384 
cocktail at room temperature, and were dounced in a 7-mL Dounce homogenizer (Sigma, cat. 1385 
P0610) for 120 strokes on ice followed by centrifuging for 10 min at 1,000 g, 4 °C, yielding post-1386 
nuclear supernatants (PNS). The PNS were then centrifuged for 20 min at 20,000 g and the 1387 
pellet was suspended by 1× Extraction Buffer by gentle pipetting, generating Crude Lysosomal 1388 
Fraction (CLF). The volume of CLF was adjusted to 2.4 mL and then equally divided into six 1389 
1.5 mL Eppendorf tubes (400 μl per tube). 253 μL of OptiPrep and 137 μL of 1× OptiPrep 1390 
Dilution Buffer were added to each CLF, and mixed by gentle pipetting. The mixture is defined 1391 
as the Diluted OptiPrep Fraction (DOF). Each DOF (0.8 mL) was loaded to an 11 × 60 mm 1392 
centrifuge tube at the top of 27% (0.4 mL) and 22.5% (0.5 mL) OptiPrep solution cushions, and 1393 
then overlaid with 16% (1 mL), 12% (0.9 mL) and 8% (0.3 mL) OptiPrep solutions. The tube 1394 
was then centrifuged on a SW60 Ti rotor (Beckman) at 150,000 g for 4 hr at 4 °C, and the 1395 
fraction at the top of 12% OptiPrep solution was collected as the crude lysosome fraction. The 1396 
fraction was diluted with two volumes of PBS, followed by centrifugation at 20,000 g for 20 min. 1397 
The supernatant was then aspirated, and the sediment was the lysosome fraction. 1398 
Measurement of v-ATPase Activity In Vitro 1399 
For each assay, lysosomes purified from two 10-cm dishes of MEFs were used. ATP hydrolysis 1400 
activity was measured using a coupled spectrophotometric method as described previously 1401 
(Shao and Forgac, 2004) with some modifications. Briefly, lysosomes were suspended in 1402 
ATPase assay buffer (50 mM NaCl, 30 mM KCl, 20 mM HEPES-NaOH, pH 7.0, 10% glycerol, 1403 
1 mM MgCl2, 1.5 mM phosphoenolpyruvate, 0.35 mM NADH, 20 U/mL pyruvate kinase, and 10 1404 
U/mL lactate dehydrogenase) with 5 μM ConA (for calculating the v-ATPase-specific ATP 1405 
hydrolysis activity) or DMSO, and warmed at 37 °C for 10 min. The assay was initiated by the 1406 
addition of 5 mM ATP, and the OD341 was continuously recorded by a SpectraMax M5 1407 
microplate reader.  1408 
ATP-dependent proton transport activity was measured by the initial rate of ATP-dependent 1409 
fluorescent quenching of FITC-dextran, as described previously (Liberman et al., 2014; 1410 
Trombetta et al., 2003). Briefly, lysosomes were loaded with FITC-dextran by incubating cells 1411 
in DMEM supplemented with 2 mg/mL FITC-dextran (final concentration) on ice for 5 min, then 1412 
transferred to a 37 °C incubator for 30 min. Cells were washed with DMEM for three times and 1413 
incubated with DMEM for another 30 min at 37 °C to allow transport of FITC-dextran to 1414 
lysosomes. Cells were collected and lysosomes were purified as described above. The 1415 
lysosomes were resuspended in assay buffer (125 mM KCl, 1 mM EDTA, 20 mM HEPES, pH 1416 
7.5, with KOH) and were balanced on ice for 1 hr, then mixed with 5 μM ConA (for calculating 1417 
the v-ATPase-specific proton transport activity) or DMSO, then warmed at 37 °C for 10 min. 1418 
Fluorescence of FITC was recorded with excitation at 490 nm and emission at 520 nm using a 1419 
SpectraMax M5 microplate reader. The initial slope of fluorescence quenching was measured 1420 
after addition of 5 mM Mg-ATP (final concentration). 1421 
Isolation of Light Organelles 1422 
Light organelles were isolated as described previously (Steinberg et al., 2010; Zoncu et al., 1423 
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2011). Briefly, cells were scraped and spun down at 200 g at room temperature, and then 1424 
resuspended in 750 μL per 15-cm dish of fractionation buffer (140 mM KCl, 1 mM EGTA, 5 mM 1425 
MgCl2, 50 mM sucrose, 20 mM HEPES, pH 7.4, supplemented with 2.5 mM ATP, amino acids 1426 
and protease inhibitor cocktail) at room temperature, and were mechanically broken by spraying 1427 
6 times through a 22G needle, yielding PNS after spinning at 2,000 g for 5 min. The PNS was 1428 
then spun at max speed for 15 min in a tabletop centrifuge. The pellets are light organelles and 1429 
supernatants are the cytosol. 1430 
In Vitro Reconstitution for Lysosomal Binding Assays 1431 
Light organelles then re-suspended with 100 μL fractionation buffer containing 10 μM FBP were 1432 
incubated at 37 °C in a thermomixer at 400 rpm for 15 min. Some 500 μL of cytosol was then 1433 
added to the mixture, followed by incubation at 37 °C for another 25 min. The mixtures were 1434 
lysed with 800 μL ODG buffer, followed by IP with antibody against LAMTOR1.  1435 
Purification of ER 1436 
Method for isolating pure ER was optimized by combining the traditional microsome-based 1437 
density gradient isolation method (Endoplasmic Reticulum Isolation Kit developed by Sigma-1438 
Aldrich) with the cell surface biotinylation reaction method (developed and optimized by Pierce). 1439 
Briefly, MEFs from 40 10-cm dishes (80% confluence) were quickly washed with ice-cold PBS 1440 
(10 mL each dish) twice, followed by incubating with 250 μg/mL of sulfo-NHS-SS-biotin (freshly 1441 
dissolved in ice-cold PBS, 10 mL each dish) for 30 min with gentle agitate on an orbital shaker 1442 
at 4 °C. Some 500 μL of 1 M Tris (pH 8.0 at 4 °C) was then added to each dish to quench the 1443 
biotinylation reaction. Cells were collected afterwards by directly scrapping, followed by 1444 
centrifugation at 600 g for 5 min, and then washed with 40 mL of ice-cold PBS twice. Cells were 1445 
then re-suspended in 10 mL of 1× Hypotonic Extraction Buffer and then incubated at 4 °C for 1446 
30 min, with gentle mixing in the middle. Cells were then centrifuged at 600 g at 4 °C for 5 min, 1447 
and the pellet was re-suspended with 6 mL of 1× Isotonic Extraction Buffer, followed by mixing 1448 
in a 7-mL Dounce homogenizer for 10 strokes. The homogenate was centrifuged at 1,000 g for 1449 
10 min at 4 °C, and the supernatant (PNS) was further centrifuged at 12,000 g for 15 min at 1450 
4 °C, yielding the supernatant as the post-mitochondrial fraction (PMF). The PMF was loaded 1451 
in two 11 × 60 mm centrifuge tubes and then centrifuged on an SW60 Ti rotor (Beckman) at 1452 
100,000 g for 1 hr at 4 °C. The pellet was re-suspended with 0.5 mL of 1× Isotonic Extraction 1453 
Buffer, and was mixed in a 2-mL Dounce homogenizer for 20 strokes, yielding the microsomal 1454 
suspension. The suspension was mixed with 0.25 mL of OptiPrep, and was carefully layered 1455 
on the top of 1 mL of 30% OptiPrep solution (by mixing 0.5 mL of OptiPrep with 0.5 mL of 1× 1456 
Isotonic Extraction Buffer) in an 11 × 60 mm centrifuge tube. Some 2 mL of 15% OptiPrep 1457 
solution (by mixing 0.5 mL of OptiPrep with 1.5 mL of 1× Isotonic Extraction Buffer) was then 1458 
carefully layered on the top of the sample. The tube was then centrifuged on an SW60 Ti rotor 1459 
at 150,000 g for 3 hr at 4 °C. The top 0.6 mL of 15% OptiPrep solution was discarded, and the 1460 
following 200 μL of fraction was collected as the crude ER fraction. The fraction was then 1461 
incubated with 100 μL of NeutrAvidin Agarose (pre-balanced by 1× Isotonic Extraction Buffer) 1462 
for another 2 hr. The supernatant was then mixed with 50 μL of 5× SDS sample buffer for 1463 
immunoblotting analysis. 1464 
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Protein Production 1465 
Full length cDNAs encoding calmodulin and CaMKK2 were cloned into pET-28a (Novagen) and 1466 
pGEX4T-1 (GE Healthcare) vectors, respectively, and transformed into the E. coli strain BL21 1467 
(DE3). The transformed cells were induced with 0.1 mM IPTG at an optical density of 1.0 at 1468 
600 nm. After incubating for another 4 hr at 30 °C, the cells were collected. For His-tagged 1469 
calmodulin, cells were homogenized in a His binding buffer (50 mM sodium phosphate, pH 7.4, 1470 
150 mM NaCl, 1% Triton X-100, 5% glycerol, and 10 mM imidazole), and for GST-tagged 1471 
CaMKK2, with a GST binding buffer (PBS supplemented with 10 mM β-mercaptoethanol and 1472 
1% Triton X-100). The homogenates were then sonicated, and were subjected to 1473 
ultracentrifugation at 150,000 g for 30 min, followed by purification of calmodulin with Nickel 1474 
Affinity Gel or CaMKK2 with Glutathione Sepharose 4 Fast Flow Gel. The Nickel Affinity Gel 1475 
was then washed with 100 times the volume of His wash buffer (50 mM sodium phosphate, pH 1476 
7.4, 150 mM NaCl, and 20 mM imidazole), and the Glutathione Sepharose gel with 100 times 1477 
the volume of PBS. Calmodulin was eluted from the resin by His elution buffer (50 mM sodium 1478 
phosphate, pH 7.4, 150 mM NaCl, and 250 mM imidazole), and CaMKK2 was eluted by GST 1479 
elution buffer (50 mM Tris–HCl, pH 8.0, and 10 mM reduced glutathione). Proteins were 1480 
concentrated to approximately 3 mg/mL by ultrafiltration (Millipore, UFC905096 for CaMKK2, 1481 
and UFC901096 for calmodulin), then subjected to a gel filtration column (GE Healthcare, 1482 
Superdex-200) balanced with an AMPK kinase assay buffer containing 50 mM MOPS, pH 7.0, 1483 
100 mM NaCl, 0.1 mM EDTA, and 10 mM MgCl2. Heterotrimeric AMPK was expressed in the 1484 
E. coli strain BL21 (DE3) as described previously (Neumann et al., 2003) and purified through 1485 
a gel filtration column as described above. 1486 
Kinetic Analysis of CaMKK2 Activity 1487 
The enzymatic activity of CaMKK2 was expressed by the activity of AMPK pre-phosphorylated 1488 
by CaMKK2. The assay was performed as described previously (Chen et al., 2009) with minor 1489 
modifications. Briefly, GST-tagged CaMKK2 was incubated with Glutathione Sepharose 4 Fast 1490 
Flow Gel (5 μg of protein/μL gel) at 4 °C for 1 hr, followed by washing in an AMPK kinase assay 1491 
buffer twice. Some 1 μL of immobilized CaMKK2 was then incubated with 5 μg of AMPK, 10 μg 1492 
of calmodulin in AMPK kinase assay buffer supplemented with 5 mM ATP and desired 1493 
concentrations of CaCl2 (total volume: 60 μL) on a thermomixer at 30 °C for 30 min. CaMKK2 1494 
was then removed by centrifugation at 2,000 g, 4 °C for 30 s, resulting in the supernatant that 1495 
contained phosphorylated AMPK. Activity of the resultant AMPK was determined by incubating 1496 
50 μL of the supernatant with 200 μL of 30 °C-pre-warmed AMPK kinase assay buffer 1497 
supplemented with 0.2 mM NADH, 1.0 mM phosphoenolpyruvate, 20 U/mL lactate 1498 
dehydrogenase, 15 U/mL pyruvate kinase, 5 mM ATP and 200 μM ACC tide 1499 
(HMRSSMSGLHLVRRR, synthesized by GenScript, China) at 30 °C. The OD341 was 1500 
continuously recorded by a SpectraMax M5 microplate reader. 1501 
Analysis of AMP/ATP and ADP/ATP Ratios  1502 
To analyze AMP/ATP and ADP/ATP ratios in mammalian cell lines, mouse liver and muscle, CE 1503 
(capillary electrophoresis)-MS was performed. Sample preparation for CE-MS was carried out 1504 
as described previously (Zhao et al., 2014; Zhao et al., 2015), with some modifications. In 1505 
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general, each measurement requires cells collected from a 10-cm dish (60-70% confluence) or 1506 
20 mg of freeze-clamped mouse liver. Cells/tissues were rinsed with 20 mL of 5% mannitol 1507 
solution (dissolved in water) and instantly frozen in liquid nitrogen. Cells/tissues were then lyzed 1508 
with 1 mL of methanol containing internal standards 1 (IS1 used to standardize the metabolite 1509 
intensity and to adjust the migration time), and cells were scrapped off from the dish. Lysate 1510 
was then mixed with 1 mL of chloroform and 400 µL of water by 20 s of vortexing. After 1511 
centrifugation at 15,000 g for another 15 min at 4 °C, 450 µL of aqueous phase was collected 1512 
and was filtrated through a 5 kDa cutoff filter (Millipore, cat. UFC3LCCNB-HMT) by centrifuging 1513 
at 10,000 g for 3 hr at 4 °C. The filtered aqueous phase was then freeze-dried in a vacuum 1514 
concentrator (Labconco, CentriVap Benchtop Centrifugal Vacuum Concentrator, equipped with 1515 
a CentriVap -84 °C Cold Trap and a Scroll Vacuum Pump) and then dissolved in water 1516 
containing internal standards 3 (IS3 to adjust the migration time). 20 µL of re-dissolved solution 1517 
was then loaded into an injection vial with a conical insert for CE-TOF MS (Agilent Technologies 1518 
7100, equipped with 6224 mass spectrometer) analysis. Data were processed using Qualitative 1519 
Analysis B.06.00. Levels of AMP, ADP, and ATP were measured using full scan mode with m/z 1520 
346.0558, 426.0221, and 505.9885, respectively. Note that a portion of ADP and ATP could 1521 
lose one phosphate group during in-source-fragmentation thus leaving same m/z ratios as AMP 1522 
and ADP, and should be corrected according to their different retention time in capillary. 1523 
Therefore, the total amount of ADP is the sum of the latter peak of the m/z 346.0558 1524 
spectrogram and the former peak of the m/z 426.0221 spectrogram, and ditto for ATP.  1525 
Measurement of NAD+ 1526 
To measure NAD+ levels in muscle, some 50 mg of fleshly excised gastrocnemius muscle was 1527 
immediately frozen in liquid nitrogen and homogenized in 1 mL of ice-cold methanol. Some 1 1528 
mL of chloroform and 400 µL of water were then added to the homogenate sequentially, 1529 
followed by 20 s of vortexing. After centrifugation at 15,000 g for 15 min at 4 °C, 350 µL of 1530 
aqueous phase was collected, lyophilized in a vacuum concentrator, and then dissolved in 500 1531 
µL of 20% methanol. The remaining solution was dried at a fume hood at room temperature for 1532 
three days to obtain the dry weight of protein (for calculating the relative concentrations of 1533 
NAD+). Measurement of NAD+ level was based on (Katsyuba et al., 2018) using a QTRAP MS 1534 
(SCIEX, QTRAP 6500 plus) interfaced with a UPLC system (Waters, ACQUITY UPLC system) 1535 
with minor modifications. In brief, 2 µL of each sample was loaded onto a SeQuant ZIC-pHILIC 1536 
column (5 µm, 100 × 2.1 mm, Merck). Mobile phase buffer A was 15 mM ammonium acetate in 1537 
water (pH adjusted to 9.7 with ammonium hydroxide), and mobile phase buffer B 90% 1538 
acetonitrile. During the analysis, the column was maintained at 40 °C and sample at 8 °C. The 1539 
gradients were as follows: t = 0-2 min, 95% B; t = 15-18 min, 45% B; t = 18-22 min, 95% B, with 1540 
a constant flow rate at 0.2 mL/min. The QTRAP mass spectrometer was run in negative mode 1541 
with multiple reactions monitoring mode (MRM), and declustering potentials and collision 1542 
energies were optimized using analytical standards of NAD+. The following transition was used 1543 
for monitoring NAD+: 662.0/540.1. The retention time of NAD+ was 10.3 min.  1544 
Determination of Lysosomal Membrane Potential 1545 
To measure FRET in MEFs, cells were first loaded with Rhodamine-PE (Rh-PE, FRET acceptor) 1546 
followed by addition of the membrane-permeant oxonol dye DiBAC4(3) (FRET donor) to the 1547 
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culture medium. The emission intensities of the donor, acceptor and FRET channels were 1548 
separately measured according to the images taken by a Zeiss LSM 780. The bleed-through 1549 
parameters of donor and acceptor were then calculated according to the values of cFRET as 1550 
described previously (Koivusalo et al., 2011). Rh-PE was freshly prepared by adding 25 μL of 1551 
1 mg/mL Rh-PE solution in CHCl3/MeOH (1:1) dropwise into 4 mL of 0.5 mg/mL fatty acid-free 1552 
BSA in PBS accompanied with vigorously vortexing for 1-2 min. MEFs grown in 35-mm glass 1553 
bottom dishes were washed with ice-cold PBS, and incubated with the Rh-PE-BSA complex for 1554 
10 min on ice to allow for the entry of this complex into the cell. Cells were then washed with 1555 
medium, and incubated at 37 °C for another 90 min. A 300 nM DiBAC4(3) was added to the 1556 
medium and the cells were balanced for 5 min at 37 °C, then washed and imaged in the live-1557 
cell incubation chamber at a regular interval. Different fields of the donor, acceptor and FRET 1558 
channels were first acquired, and the filter set parameters (listed as excitation/emission filters, 1559 
all in nanometers ± bandwidth) used for FRET calculation were as follows: donor DiBAC4(3) at 1560 
475 ± 60/510 ± 40, acceptor Rh-PE at 543 ± 22/580 ± 25, and FRET at 475 ± 60/580 ± 25. For 1561 
the determination of the donor and acceptor bleed-through coefficients, samples loaded with 1562 
donor or acceptor only were imaged. Cells loaded with donor alone, showed negligible cFRET 1563 
signal. Similarly, cFRET was virtually absent when only the acceptor was present. In MEFs that 1564 
had been loaded with both the donor and the acceptor, the cFRET signal was detectable and 1565 
recorded, and was calculated using the method as described previously (Koivusalo et al., 2011). 1566 
All parameters, including exposure times and camera gains, were kept constant across each 1567 
experiment. Images were background-subtracted before analysis. 1568 
QUANTIFICATION AND STATISTICAL ANALYSIS 1569 
1-way or 2-way ANOVA with post hoc analysis was used to compare values among different 1570 
experimental groups. For experiments with only two groups, a two-tailed Student’s t test was 1571 
used as specified in the figure legends. For ANOVA, the homogeneity of variance was tested 1572 
by Levene’s test. If the results are similar, the Tukey's test was preceded, and if not, the Games-1573 
Howell’s test was preceded. Similar procedures were followed when Student's t test was 1574 
performed. No samples or animals were excluded from the analysis. Tests were performed with 1575 
SPSS Statistics 17.0 program or Prism 6, and p < 0.05 was considered statistically significant. 1576 
Statistical significance is shown as * p < 0.05, ** p < 0.01, *** p < 0.001; N.S., not significant. 1577 
DATA AND SOFTWARE AVAILABILITY 1578 
All software and data used are freely available either online through various servers (see Key 1579 
Resources Table). Source data for blot quantification can be found in Mendeley Data: 1580 
https://data.mendeley.com/datasets/p3zgm58ksw/draft?a=10c923e7-0295-4f9c-ad63-1581 
e7e811c789da 1582 
 1583 
